Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:pyrazines
go back to main search page
Accession:CHEBI:38314 term browser browse the term
Synonyms:xref_mesh: MESH:D011719


show annotations for term's descendants           Sort by:
pyrazines term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Chrna4 cholinergic receptor nicotinic alpha 4 subunit multiple interactions ISO Pyrazines binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] CTD PMID:21962147 NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957 		JBrowse link
G Chrnb2 cholinergic receptor nicotinic beta 2 subunit multiple interactions ISO Pyrazines binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] CTD PMID:21962147 NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions
increases expression
increases activity		 EXP allyl sulfide inhibits the reaction [Pyrazines results in increased activity of CYP2E1 protein]; allyl sulfide inhibits the reaction [Pyrazines results in increased expression of CYP2E1 protein] CTD PMID:8117321 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression ISO Pyrazines analog results in increased expression of GCLC mRNA CTD PMID:25056784 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 decreases expression ISO Pyrazines results in decreased expression of GSTA1 protein CTD PMID:7986210 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 decreases expression ISO Pyrazines results in decreased expression of GSTM1 protein CTD PMID:7986210 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Pyrazines inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK1 protein modified form] CTD PMID:22342441 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Pyrazines inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK3 protein modified form] CTD PMID:22342441 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Pyrazines inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Pyrazines inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] CTD PMID:22342441 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 decreases activity ISO Pyrazines results in decreased activity of PTGS1 protein CTD PMID:22342441 NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases activity ISO Pyrazines results in decreased activity of PTGS2 protein CTD PMID:22342441 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
5-(N,N-hexamethylene)amiloride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO 5-(N,N-hexamethylene)amiloride results in increased expression of DDIT3 mRNA CTD PMID:19302589 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 affects expression ISO 5-(N,N-hexamethylene)amiloride affects the expression of HSP90B1 mRNA CTD PMID:19302589 NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 affects expression ISO 5-(N,N-hexamethylene)amiloride affects the expression of HSPA5 mRNA CTD PMID:19302589 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO 5-(N,N-hexamethylene)amiloride results in increased expression of PPP1R15A mRNA CTD PMID:19302589 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO 5-(N,N-hexamethylene)amiloride results in increased expression of PTGS2 mRNA CTD PMID:19302589 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Serpinb1a serpin family B member 1A multiple interactions ISO 5-(N,N-hexamethylene)amiloride results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1 protein modified form CTD PMID:25447644 NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102 		JBrowse link
5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acadm acyl-CoA dehydrogenase medium chain increases expression ISO acipimox results in increased expression of ACADM mRNA CTD PMID:25352640 NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147 		JBrowse link
G Atp5f1c ATP synthase F1 subunit gamma increases expression ISO acipimox results in increased expression of ATP5F1C mRNA CTD PMID:25352640 NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367 		JBrowse link
G Cd36 CD36 molecule increases expression ISO acipimox results in increased expression of CD36 mRNA CTD PMID:25352640 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903 		JBrowse link
G Cs citrate synthase increases expression ISO acipimox results in increased expression of CS mRNA CTD PMID:25352640 NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421 		JBrowse link
G Cycs cytochrome c, somatic increases expression ISO acipimox results in increased expression of CYCS mRNA CTD PMID:25352640 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G D2hgdh D-2-hydroxyglutarate dehydrogenase decreases expression ISO acipimox results in decreased expression of D2HGDH mRNA CTD PMID:25352640 NCBI chr 9:94,350,555...94,368,384
Ensembl chr 9:94,350,576...94,368,382 		JBrowse link
G Dlst dihydrolipoamide S-succinyltransferase increases expression ISO acipimox results in increased expression of DLST mRNA CTD PMID:25352640 NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296 		JBrowse link
G Foxo1 forkhead box O1 increases expression ISO acipimox results in increased expression of FOXO1 mRNA CTD PMID:25352640 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790 		JBrowse link
G Ghrh growth hormone releasing hormone affects response to substance ISO acipimox affects the susceptibility to GHRH protein CTD PMID:8923850 NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889 		JBrowse link
G Hspd1 heat shock protein family D (Hsp60) member 1 increases expression ISO acipimox results in increased expression of HSPD1 protein CTD PMID:25352640 NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha increases expression ISO acipimox results in increased expression of IDH3A mRNA CTD PMID:25352640 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084 		JBrowse link
G Idh3b isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit beta decreases expression ISO acipimox results in decreased expression of IDH3B mRNA CTD PMID:25352640 NCBI chr 3:117,481,845...117,486,909
Ensembl chr 3:117,481,845...117,486,982 		JBrowse link
G Ins2 insulin 2 decreases expression ISO acipimox results in decreased expression of INS protein CTD PMID:8923850 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G L2hgdh L-2-hydroxyglutarate dehydrogenase decreases expression ISO acipimox results in decreased expression of L2HGDH mRNA CTD PMID:25352640 NCBI chr 6:88,164,429...88,205,585
Ensembl chr 6:88,164,440...88,205,578 		JBrowse link
G Ldhb lactate dehydrogenase B increases expression ISO acipimox results in increased expression of LDHB mRNA CTD PMID:25352640 NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403 		JBrowse link
G Mfn2 mitofusin 2 increases expression ISO acipimox results in increased expression of MFN2 mRNA CTD PMID:25352640 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342 		JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I increases expression ISO acipimox results in increased expression of COX1 mRNA; acipimox results in increased expression of COX1 protein CTD PMID:25352640 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867 		JBrowse link
G Mt-co2 mitochondrially encoded cytochrome c oxidase II increases expression ISO acipimox results in increased expression of COX2 mRNA CTD PMID:25352640 NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689 		JBrowse link
G Mt-nd6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 decreases expression ISO acipimox results in decreased expression of ND6 mRNA CTD PMID:25352640 NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061 		JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 decreases expression ISO acipimox results in decreased expression of NDUFA1 mRNA CTD PMID:25352640 NCBI chr  X:116,424,223...116,427,875
Ensembl chr  X:116,424,223...116,428,633 		JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 increases expression ISO acipimox results in increased expression of NDUFA2 mRNA CTD PMID:25352640 NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076 		JBrowse link
G Ndufb1 NADH:ubiquinone oxidoreductase subunit B1 decreases expression ISO acipimox results in decreased expression of NDUFB1 mRNA CTD PMID:25352640 NCBI chr 6:121,115,649...121,124,055 JBrowse link
G Ndufv1 NADH:ubiquinone oxidoreductase core subunit V1 decreases expression ISO acipimox results in decreased expression of NDUFV1 mRNA CTD PMID:25352640 NCBI chr 1:201,300,365...201,305,461
Ensembl chr 1:201,299,985...201,305,466 		JBrowse link
G Ogdh oxoglutarate dehydrogenase decreases expression ISO acipimox results in decreased expression of OGDH mRNA CTD PMID:25352640 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479 		JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 decreases expression ISO acipimox results in decreased expression of PDK1 mRNA CTD PMID:25352640 NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038 		JBrowse link
G Pdp2 pyruvate dehydrogenase phosphatase catalytic subunit 2 increases expression ISO acipimox results in increased expression of PDP2 mRNA CTD PMID:25352640 NCBI chr19:386,408...394,068
Ensembl chr19:386,406...394,074 		JBrowse link
G Pdpr pyruvate dehydrogenase phosphatase regulatory subunit increases expression ISO acipimox results in increased expression of PDPR mRNA CTD PMID:25352640 NCBI chr19:39,065,226...39,109,695
Ensembl chr19:39,065,157...39,109,688 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression ISO acipimox results in increased expression of PPARA mRNA CTD PMID:25352640 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression ISO acipimox results in increased expression of PPARGC1A mRNA CTD PMID:25352640 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656 		JBrowse link
G Slc16a3 solute carrier family 16 member 3 increases expression ISO acipimox results in increased expression of SLC16A3 mRNA CTD PMID:25352640 NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562 		JBrowse link
G Sod2 superoxide dismutase 2 increases expression ISO acipimox results in increased expression of SOD2 mRNA CTD PMID:25352640 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sod3 superoxide dismutase 3 increases expression ISO acipimox results in increased expression of SOD3 mRNA CTD PMID:25352640 NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990 		JBrowse link
G Suclg2 succinate-CoA ligase GDP-forming subunit beta decreases expression ISO acipimox results in decreased expression of SUCLG2 mRNA CTD PMID:25352640 NCBI chr 4:128,067,031...128,337,146
Ensembl chr 4:128,067,033...128,337,170 		JBrowse link
G Tfam transcription factor A, mitochondrial increases expression ISO acipimox results in increased expression of TFAM mRNA CTD PMID:25352640 NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292 		JBrowse link
G Tnnt1 troponin T1, slow skeletal type increases expression ISO acipimox results in increased expression of TNNT1 mRNA CTD PMID:25352640 NCBI chr 1:69,306,362...69,316,721
Ensembl chr 1:69,306,362...69,316,721 		JBrowse link
G Ucp2 uncoupling protein 2 increases expression ISO acipimox results in increased expression of UCP2 mRNA CTD PMID:25352640 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611 		JBrowse link
G Ucp3 uncoupling protein 3 decreases expression
multiple interactions		 ISO acipimox results in decreased expression of UCP3 mRNA
[Albuterol co-treated with acipimox] results in decreased expression of UCP3 mRNA		 CTD PMID:12824081 PMID:25352640 NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762 		JBrowse link
G Uqcrh ubiquinol-cytochrome c reductase hinge protein increases expression ISO acipimox results in increased expression of UQCRH mRNA CTD PMID:25352640 NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242 		JBrowse link
amiloride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acan aggrecan affects expression EXP Amiloride affects the expression of ACAN mRNA CTD PMID:20454829 NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627 		JBrowse link
G Agt angiotensinogen multiple interactions
increases expression		 EXP
ISO		 Amiloride inhibits the reaction [AGT protein results in increased expression of ATP1A1 mRNA]
Amiloride results in increased expression of AGT protein modified form		 CTD PMID:7357812 PMID:14630723 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Amiloride results in decreased phosphorylation of and results in decreased activity of AKT1 protein; Okadaic Acid inhibits the reaction [Amiloride results in decreased phosphorylation of AKT1 protein] CTD PMID:15607733 PMID:16059913 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Alb albumin multiple interactions EXP Amiloride inhibits the reaction [ALB protein results in increased expression of CCL2 protein] CTD PMID:11340305 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Aoc1 amine oxidase, copper containing 1 affects binding
multiple interactions
decreases activity		 ISO
EXP		 Amiloride binds to AOC1 protein
Amiloride inhibits the reaction [Phenylamil binds to Aoc1 protein]
Amiloride binds to Aoc1 protein
Amiloride inhibits the reaction [AOC1 protein results in increased degradation of Putrescine]
Amiloride results in decreased activity of AOC1 protein		 CTD
RGD		 PMID:2217167 PMID:8144586 PMID:8375402 PMID:8375402 RGD:724757, RGD:724757 NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840 		JBrowse link
G Asic3 acid sensing ion channel subunit 3 affects response to substance ISO ASIC3 protein affects the susceptibility to Amiloride CTD PMID:12037186 NCBI chr 4:10,760,509...10,764,987
Ensembl chr 4:10,760,597...10,764,643 		JBrowse link
G Atp1a1 ATPase Na+/K+ transporting subunit alpha 1 multiple interactions EXP Amiloride inhibits the reaction [AGT protein results in increased expression of ATP1A1 mRNA] CTD PMID:14630723 NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837 		JBrowse link
G Atp6v1b1 ATPase H+ transporting V1 subunit B1 multiple interactions EXP [Furosemide co-treated with Amiloride] results in increased expression of ATP6V1B1 protein CTD PMID:17311909 NCBI chr 4:116,223,799...116,242,475
Ensembl chr 4:116,223,799...116,242,475 		JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H multiple interactions ISO Amiloride inhibits the reaction [CACNA1H protein results in increased transport of Calcium] CTD PMID:9930755 PMID:11897840 NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376 		JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions ISO Amiloride inhibits the reaction [Acids results in increased secretion of CALCA protein] CTD PMID:20100279 NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO
EXP		 Amiloride promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP3 protein]
Amiloride inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]		 CTD PMID:15607733 PMID:16059913 PMID:34656704 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO Amiloride promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP8 protein] CTD PMID:15607733 PMID:16059913 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP9 protein] CTD PMID:16059913 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
decreases expression		 ISO
EXP		 Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 protein]
Amiloride results in decreased expression of CCL2 mRNA; Amiloride results in decreased expression of CCL2 protein
Amiloride inhibits the reaction [ALB protein results in increased expression of CCL2 protein]; Amiloride inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Amiloride inhibits the reaction [Ouabain results in increased expression of CCL2 protein]; Sodium deficiency inhibits the reaction [Amiloride results in decreased expression of CCL2 mRNA]; Sodium deficiency inhibits the reaction [Amiloride results in decreased expression of CCL2 protein]		 CTD PMID:11340305 PMID:12107048 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] CTD PMID:11420121 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938 		JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO Amiloride results in decreased expression of CCNB1 protein CTD PMID:9458082 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Cftr CF transmembrane conductance regulator increases activity ISO
EXP		 Amiloride results in increased activity of CFTR protein
Amiloride increases activity of Cftr protein in nasal cavity epithelium		 CTD
RGD		 PMID:15246976 PMID:31942562 RGD:126928119 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756 		JBrowse link
G Col2a1 collagen type II alpha 1 chain affects expression EXP Amiloride affects the expression of COL2A1 mRNA CTD PMID:20454829 NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL2 protein] CTD PMID:11420121 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO Amiloride promotes the reaction [TNFSF10 protein affects the localization of CYCS protein] CTD PMID:15607733 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity ISO Amiloride results in decreased activity of CYP1A1 protein CTD PMID:33814510 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Amiloride results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO Amiloride inhibits the reaction [Tunicamycin results in increased expression of DDIT3] CTD PMID:20015086 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dysf dysferlin decreases expression ISO Amiloride results in decreased expression of DYSF mRNA CTD PMID:15535137 NCBI chr 4:116,490,877...116,690,709
Ensembl chr 4:116,490,616...116,690,709 		JBrowse link
G Eif2a eukaryotic translation initiation factor 2A increases phosphorylation ISO Amiloride results in increased phosphorylation of EIF2A protein CTD PMID:20015086 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 decreases phosphorylation ISO Amiloride results in decreased phosphorylation of ERBB2 protein CTD PMID:16059913 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO Amiloride inhibits the reaction [Tunicamycin results in increased phosphorylation of and results in increased activity of ERN1 protein] CTD PMID:20015086 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions		 ISO Amiloride results in increased expression of FOS mRNA
Amiloride inhibits the reaction [Acids results in increased expression of and results in increased localization of FOS protein]		 CTD PMID:12730611 PMID:16769263 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Grip1 glutamate receptor interacting protein 1 affects response to substance ISO GRIP1 gene SNP affects the susceptibility to Amiloride CTD PMID:25622337 NCBI chr 7:54,934,856...55,592,274
Ensembl chr 7:54,934,250...55,592,273 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO Amiloride inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; Amiloride inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein] CTD PMID:20015086 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Ifng interferon gamma multiple interactions ISO Amiloride inhibits the reaction [IFNG protein results in increased expression of PLAUR mRNA]
Amiloride inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with IFNG protein] results in increased secretion of IL12B protein]		 CTD PMID:11420121 PMID:12070711 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO Amiloride inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with IFNG protein] results in increased secretion of IL12B protein] CTD PMID:11420121 NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Amiloride inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Amiloride inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Amiloride inhibits the reaction [IL1B protein results in increased expression of SELE protein]; Amiloride inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; Amiloride inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; Amiloride inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] CTD PMID:12065299 PMID:12107048 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Itgal integrin subunit alpha L multiple interactions ISO Amiloride inhibits the reaction [TNF protein results in increased expression of ITGAL mRNA]; Amiloride inhibits the reaction [TNF protein results in increased expression of ITGAL protein] CTD PMID:10198263 NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732 		JBrowse link
G Klk1 kallikrein 1 multiple interactions
increases response to substance		 ISO KLK1 protein affects the susceptibility to [Amiloride results in increased secretion of Sodium]
KLK1 protein results in increased susceptibility to Amiloride		 CTD PMID:18086683 NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:94,642,687...94,646,754 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Amiloride inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein] CTD PMID:12065299 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Amiloride inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein] CTD PMID:12065299 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO Amiloride inhibits the reaction [azaspiracid results in increased phosphorylation of and affects the localization of MAPK8 protein] CTD PMID:19815690 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO Amiloride inhibits the reaction [azaspiracid results in increased phosphorylation of and affects the localization of MAPK9 protein] CTD PMID:19815690 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Myf5 myogenic factor 5 increases expression ISO Amiloride results in increased expression of MYF5 mRNA CTD PMID:15535137 NCBI chr 7:42,802,946...42,806,177
Ensembl chr 7:42,802,946...42,806,177 		JBrowse link
G Myl12b myosin light chain 12B decreases phosphorylation ISO Amiloride results in decreased phosphorylation of MRLC2 protein CTD PMID:11078707 NCBI chr 9:110,873,855...110,888,187 JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO Amiloride inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein] CTD PMID:12065299 PMID:12107048 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of and results in decreased expression of NFKBIA protein] CTD PMID:12107048 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Lipopolysaccharides inhibits the reaction [Amiloride results in increased expression of NOS2] CTD PMID:21356098 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Okadaic Acid inhibits the reaction [Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]] CTD PMID:15607733 PMID:16059913 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pdpk1 3-phosphoinositide dependent protein kinase-1 decreases phosphorylation ISO Amiloride results in decreased phosphorylation of PDPK1 protein CTD PMID:16059913 NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623 		JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 decreases uptake ISO Amiloride results in decreased uptake of PDX1 protein CTD PMID:16405074 NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064 		JBrowse link
G Pkd2 polycystin 2, transient receptor potential cation channel multiple interactions ISO Amiloride results in decreased activity of [PKD2 protein binds to PKD2 protein]; Amiloride results in decreased activity of [PKD2 protein binds to TRPC1 protein] CTD PMID:19193631 NCBI chr14:5,237,135...5,280,455
Ensembl chr14:5,237,135...5,280,825 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions
decreases activity		 ISO Amiloride inhibits the reaction [PLAU protein results in increased degradation of PLG protein]
Amiloride results in decreased activity of PLAU protein		 CTD PMID:8921802 PMID:11454671 PMID:14644129 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Plaur plasminogen activator, urokinase receptor multiple interactions ISO Amiloride inhibits the reaction [IFNA2 protein results in increased expression of PLAUR mRNA]; Amiloride inhibits the reaction [IFNG protein results in increased expression of PLAUR mRNA] CTD PMID:12070711 NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595 		JBrowse link
G Plg plasminogen multiple interactions ISO Amiloride inhibits the reaction [PLAU protein results in increased degradation of PLG protein] CTD PMID:14644129 NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786 		JBrowse link
G Ppp1ca protein phosphatase 1 catalytic subunit alpha decreases phosphorylation
multiple interactions		 ISO Amiloride results in decreased phosphorylation of PPP1CA protein
Okadaic Acid inhibits the reaction [Amiloride results in decreased phosphorylation of PPP1CA protein]		 CTD PMID:16059913 NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO
EXP		 Amiloride inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
Amiloride inhibits the reaction [Doxorubicin results in increased expression of PTGS2 protein]		 CTD PMID:17237260 PMID:34656704 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO
EXP		 Amiloride inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Amiloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein]
Amiloride inhibits the reaction [Doxorubicin results in increased expression of RELA protein]		 CTD PMID:12065299 PMID:12107048 PMID:34656704 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Scnn1a sodium channel epithelial 1 subunit alpha multiple interactions
affects activity		 ISO
EXP		 Amiloride inhibits the reaction [[SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] which results in increased transport of Sodium]; Amiloride results in decreased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]; Amiloride results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]
[farglitazar co-treated with Amiloride] results in increased expression of SCNN1A mRNA
Amiloride affects the activity of SCNN1A protein		 CTD PMID:8617496 PMID:15475592 PMID:18398334 PMID:18665318 PMID:19359370 NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181 		JBrowse link
G Scnn1b sodium channel epithelial 1 subunit beta multiple interactions
affects activity		 ISO Amiloride inhibits the reaction [[SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] which results in increased transport of Sodium]; Amiloride results in decreased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]; Amiloride results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]
Amiloride affects the activity of SCNN1B protein		 CTD PMID:8617496 PMID:18398334 PMID:18665318 PMID:19359370 NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451 		JBrowse link
G Scnn1g sodium channel epithelial 1 subunit gamma affects activity
multiple interactions		 ISO Amiloride affects the activity of SCNN1G protein
Amiloride inhibits the reaction [[SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] which results in increased transport of Sodium]; Amiloride results in decreased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]; Amiloride results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]		 CTD PMID:8617496 PMID:18398334 PMID:18665318 PMID:19359370 NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816 		JBrowse link
G Sele selectin E multiple interactions ISO Amiloride inhibits the reaction [IL1B protein results in increased expression of SELE protein] CTD PMID:12107048 NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741 		JBrowse link
G Slc12a4 solute carrier family 12 member 4 multiple interactions ISO Amiloride inhibits the reaction [SLC12A4 protein results in increased transport of Potassium] CTD PMID:11703599 NCBI chr19:33,838,418...33,860,369
Ensembl chr19:33,838,419...33,860,331 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Amiloride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Slc26a4 solute carrier family 26 member 4 multiple interactions EXP [Furosemide co-treated with Amiloride] affects the localization of SLC26A4 protein CTD PMID:17311909 NCBI chr 6:48,107,575...48,153,762
Ensembl chr 6:48,107,588...48,145,703 		JBrowse link
G Slc31a1 solute carrier family 31 member 1 multiple interactions ISO Amiloride inhibits the reaction [Cisplatin results in increased degradation of SLC31A1 protein] CTD PMID:17108132 NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228 		JBrowse link
G Slc47a1 solute carrier family 47 member 1 decreases activity
multiple interactions		 ISO Amiloride results in decreased activity of SLC47A1 protein
Amiloride inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]		 CTD PMID:16928787 PMID:22419765 NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637 		JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions ISO Amiloride inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904 		JBrowse link
G Slc52a3 solute carrier family 52 member 3 multiple interactions EXP Amiloride inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin] CTD PMID:19122205 NCBI chr 3:140,498,924...140,515,845
Ensembl chr 3:140,509,473...140,514,096 		JBrowse link
G Slc9a1 solute carrier family 9 member A1 multiple interactions EXP Amiloride inhibits the reaction [Doxorubicin results in increased expression of SLC9A1 protein] CTD PMID:34656704 NCBI chr 5:145,576,341...145,629,630
Ensembl chr 5:145,576,334...145,629,624 		JBrowse link
G Slc9a2 solute carrier family 9 member A2 multiple interactions EXP [Amiloride results in decreased activity of SLC9A2 protein] which results in decreased transport of Chlorides; [Amiloride results in decreased activity of SLC9A2 protein] which results in decreased transport of Sodium CTD PMID:10958346 NCBI chr 9:42,932,001...43,014,447
Ensembl chr 9:42,931,346...43,014,444 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP		 Amiloride inhibits the reaction [TNF protein results in increased expression of ITGAL mRNA]; Amiloride inhibits the reaction [TNF protein results in increased expression of ITGAL protein]; Lipopolysaccharides inhibits the reaction [Amiloride results in increased expression of TNF]
Amiloride inhibits the reaction [Doxorubicin results in increased expression of TNF protein]		 CTD PMID:10198263 PMID:21356098 PMID:34656704 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO Amiloride promotes the reaction [TNFSF10 protein affects the localization of CYCS protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP3 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP8 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of and results in increased activity of CASP9 protein]; Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Okadaic Acid inhibits the reaction [Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]] CTD PMID:15607733 PMID:16059913 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Trpa1 transient receptor potential cation channel, subfamily A, member 1 multiple interactions ISO Amiloride inhibits the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein] CTD PMID:15843607 NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570 		JBrowse link
G Trpc1 transient receptor potential cation channel, subfamily C, member 1 multiple interactions ISO Amiloride results in decreased activity of [PKD2 protein binds to TRPC1 protein] CTD PMID:19193631 NCBI chr 8:96,263,322...96,314,220
Ensembl chr 8:96,263,329...96,314,276 		JBrowse link
G Trpc6 transient receptor potential cation channel, subfamily C, member 6 decreases activity ISO Amiloride results in decreased activity of TRPC6 protein CTD PMID:11179201 NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO Amiloride results in decreased expression of VEGFA mRNA; Amiloride results in decreased expression of VEGFA protein CTD PMID:16884771 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO Amiloride inhibits the reaction [Tunicamycin results in increased splicing of XBP1 mRNA] CTD PMID:20015086 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693 		JBrowse link
Benzamil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aoc1 amine oxidase, copper containing 1 affects binding
multiple interactions		 ISO
EXP		 benzamil binds to AOC1 protein
Benzamil binds to Aoc1 protein
Benzamil inhibits the reaction [Phenylamil binds to Aoc1 protein]		 CTD
RGD		 PMID:2217167 PMID:8375402 PMID:8375402 RGD:724757, RGD:724757 NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840 		JBrowse link
G Bmp6 bone morphogenetic protein 6 multiple interactions ISO benzamil inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] CTD PMID:25633564 NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365 		JBrowse link
G Hamp hepcidin antimicrobial peptide multiple interactions
decreases expression		 ISO benzamil inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]
benzamil results in decreased expression of HAMP mRNA		 CTD PMID:25633564 NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891 		JBrowse link
G Ifng interferon gamma multiple interactions ISO benzamil inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with IFNG protein] results in increased secretion of IL12B protein] CTD PMID:11420121 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO benzamil inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with IFNG protein] results in increased secretion of IL12B protein] CTD PMID:11420121 NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903 		JBrowse link
G Nefl neurofilament light chain multiple interactions EXP benzamil inhibits the reaction [Rotenone results in decreased expression of NEFL mRNA] CTD PMID:31969611 NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793 		JBrowse link
G Sct secretin decreases activity ISO benzamil results in decreased activity of SCT protein CTD PMID:10880878 NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658 		JBrowse link
G Slc9a7 solute carrier family 9 member A7 decreases activity ISO benzamil results in decreased activity of SLC9A7 protein CTD PMID:11279194 NCBI chr  X:2,214,064...2,395,052
Ensembl chr  X:2,214,441...2,388,012 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions ISO
EXP		 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [resiniferatoxin inhibits the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester promotes the reaction [resiniferatoxin promotes the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; [Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein; Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]]; resiniferatoxin inhibits the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]; resiniferatoxin promotes the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]
[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein; Cyclosporine affects the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Ionomycin inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]; Tacrolimus affects the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Tetradecanoylphorbol Acetate affects the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]		 CTD PMID:19553475 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513 		JBrowse link
bortezomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca2 ATP binding cassette subfamily A member 2 decreases expression ISO Bortezomib results in decreased expression of ABCA2 mRNA CTD PMID:20977926 NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
decreases expression
decreases activity		 ISO [Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein
Bortezomib results in decreased activity of ABCB1 protein		 CTD PMID:25576094 PMID:30482226 PMID:33775688 PMID:34915026 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of ABCC1 mRNA
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein		 CTD PMID:20977926 PMID:33775688 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Bortezomib results in increased expression of ABCC2 mRNA CTD PMID:21215737 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression ISO Bortezomib results in decreased expression of ABCC4 mRNA CTD PMID:20977926 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abhd16a abhydrolase domain containing 16A, phospholipase increases expression ISO Bortezomib results in increased expression of ABHD16A mRNA CTD PMID:20977926 NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927 		JBrowse link
G Abhd2 abhydrolase domain containing 2, acylglycerol lipase increases expression ISO Bortezomib results in increased expression of ABHD2 mRNA CTD PMID:20977926 NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061 		JBrowse link
G Abi1 abl-interactor 1 increases expression ISO Bortezomib results in increased expression of ABI1 mRNA CTD PMID:20977926 NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] CTD PMID:15039284 PMID:17495969 PMID:21195056 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065 		JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO [Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form CTD PMID:20454656 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131 		JBrowse link
G Acot7 acyl-CoA thioesterase 7 decreases expression ISO Bortezomib results in decreased expression of ACOT7 mRNA CTD PMID:20977926 NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309 		JBrowse link
G Adam10 ADAM metallopeptidase domain 10 decreases expression ISO Bortezomib results in decreased expression of ADAM10 mRNA CTD PMID:20977926 NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889 		JBrowse link
G Adm adrenomedullin multiple interactions
decreases expression		 ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA		 CTD PMID:20471514 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654 		JBrowse link
G Aff1 ALF transcription elongation factor 1 increases expression ISO Bortezomib results in increased expression of AFF1 mRNA CTD PMID:20977926 NCBI chr14:5,861,188...6,024,196
Ensembl chr14:5,863,961...6,024,729 		JBrowse link
G Aff4 ALF transcription elongation factor 4 increases expression ISO Bortezomib results in increased expression of AFF4 mRNA CTD PMID:20977926 NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751 		JBrowse link
G Afg2a AFG2 AAA ATPase homolog A increases expression ISO Bortezomib results in increased expression of AFG2A mRNA CTD PMID:20977926 NCBI chr 2:120,306,417...120,497,707
Ensembl chr 2:120,306,412...120,497,705 		JBrowse link
G Ager advanced glycosylation end product-specific receptor multiple interactions
increases expression		 EXP Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] CTD PMID:35121005 NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078 		JBrowse link
G Agk acylglycerol kinase decreases expression ISO Bortezomib results in decreased expression of AGK mRNA CTD PMID:20977926 NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934 		JBrowse link
G Agrn agrin decreases expression ISO Bortezomib results in decreased expression of AGRN mRNA CTD PMID:20977926 NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003 		JBrowse link
G Agtpbp1 ATP/GTP binding carboxypeptidase 1 increases expression ISO Bortezomib results in increased expression of AGTPBP1 mRNA CTD PMID:20977926 NCBI chr17:5,120,540...5,238,874
Ensembl chr17:5,120,609...5,238,869 		JBrowse link
G Agtrap angiotensin II receptor-associated protein decreases expression ISO Bortezomib results in decreased expression of AGTRAP mRNA CTD PMID:20977926 NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 affects localization
multiple interactions		 ISO Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein		 CTD PMID:12893773 PMID:16024631 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256 		JBrowse link
G Aifm2 AIF family member 2 increases expression ISO Bortezomib results in increased expression of AIFM2 mRNA CTD PMID:20977926 NCBI chr20:29,654,283...29,679,239
Ensembl chr20:29,652,927...29,679,236 		JBrowse link
G Aim2 absent in melanoma 2 increases expression ISO Bortezomib results in increased expression of AIM2 mRNA CTD PMID:20977926 NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975 		JBrowse link
G Airim AFG2 interacting ribosome maturation factor increases expression ISO Bortezomib results in increased expression of AIRIM mRNA CTD PMID:20977926 NCBI chr 5:137,198,688...137,205,912
Ensembl chr 5:137,198,720...137,204,026 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 increases expression ISO Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein CTD PMID:21215737 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157 		JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions
increases expression		 ISO [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA
Bortezomib results in increased expression of AKR1C1 mRNA		 CTD PMID:21215737 PMID:25913414 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 affects expression ISO Bortezomib affects the expression of AKR1C2 mRNA CTD PMID:21215737 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO Bortezomib results in increased expression of AKR1C3 mRNA CTD PMID:21215737 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA CTD PMID:25522274 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases activity		 ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein		 CTD PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Alad aminolevulinate dehydratase decreases activity
multiple interactions		 ISO Bortezomib results in decreased activity of ALAD protein
Curcumin inhibits the reaction [Bortezomib results in decreased activity of ALAD protein]		 CTD PMID:25352650 NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474 		JBrowse link
G Aldh18a1 aldehyde dehydrogenase 18 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH18A1 mRNA CTD PMID:20977926 NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890 		JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH5A1 mRNA CTD PMID:20977926 NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677 		JBrowse link
G Aldh6a1 aldehyde dehydrogenase 6 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH6A1 mRNA CTD PMID:20977926 NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656 		JBrowse link
G Alox12 arachidonate 12-lipoxygenase, 12S type increases response to substance ISO ALOX12 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542 		JBrowse link
G Anapc11 anaphase promoting complex subunit 11 decreases expression ISO Bortezomib results in decreased expression of ANAPC11 mRNA CTD PMID:17659339 NCBI chr10:105,875,209...105,886,307 JBrowse link
G Anapc5 anaphase-promoting complex subunit 5 decreases expression
increases expression		 ISO Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA		 CTD PMID:17895889 PMID:20977926 NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781 		JBrowse link
G Ankrd9 ankyrin repeat domain 9 increases expression ISO Bortezomib results in increased expression of ANKRD9 mRNA CTD PMID:20977926 NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923 		JBrowse link
G Ano10 anoctamin 10 increases expression ISO Bortezomib results in increased expression of ANO10 mRNA CTD PMID:20977926 NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670 		JBrowse link
G Ap1s1 adaptor related protein complex 1 subunit sigma 1 decreases expression ISO Bortezomib results in decreased expression of AP1S1 mRNA CTD PMID:20977926 NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713 		JBrowse link
G Ap2a1 adaptor related protein complex 2 subunit alpha 1 decreases expression ISO Bortezomib results in decreased expression of AP2A1 mRNA CTD PMID:20977926 NCBI chr 1:95,384,306...95,414,170
Ensembl chr 1:95,384,309...95,414,147 		JBrowse link
G Apobr apolipoprotein B receptor decreases expression ISO Bortezomib results in decreased expression of APOBR mRNA CTD PMID:20977926 NCBI chr 1:181,169,019...181,173,206
Ensembl chr 1:181,168,916...181,173,528 		JBrowse link
G Apol9a apolipoprotein L9a decreases expression ISO Bortezomib results in decreased expression of APOL4 mRNA CTD PMID:20977926 NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649 		JBrowse link
G Apool apolipoprotein O-like increases expression ISO Bortezomib results in increased expression of APOOL mRNA CTD PMID:20977926 NCBI chr  X:77,377,723...77,443,672
Ensembl chr  X:77,377,781...77,443,900 		JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) increases expression ISO Bortezomib results in increased expression of AQP3 mRNA CTD PMID:20977926 NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720 		JBrowse link
G Ar androgen receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:25752796 PMID:30818834 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Arf6 ARF GTPase 6 increases expression ISO Bortezomib results in increased expression of ARF6 mRNA CTD PMID:20977926 NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114 		JBrowse link
G Arfgap1 ARF GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARFGAP1 mRNA CTD PMID:20977926 NCBI chr 3:168,084,560...168,099,948
Ensembl chr 3:168,084,614...168,099,933 		JBrowse link
G Arhgap1 Rho GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARHGAP1 mRNA CTD PMID:20977926 NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396 		JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha decreases expression ISO Bortezomib results in decreased expression of ARHGDIA mRNA CTD PMID:20977926 NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023 		JBrowse link
G Arid3b AT-rich interaction domain 3B multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA CTD PMID:25522274 NCBI chr 8:58,193,268...58,240,901
Ensembl chr 8:58,193,418...58,238,318 		JBrowse link
G Arl4c ARF like GTPase 4C decreases expression ISO Bortezomib results in decreased expression of ARL4C mRNA CTD PMID:20977926 NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513 		JBrowse link
G Arl8a ARF like GTPase 8A increases expression ISO Bortezomib results in increased expression of ARL8A mRNA CTD PMID:20977926 NCBI chr13:46,585,845...46,594,851
Ensembl chr13:46,585,845...46,594,851 		JBrowse link
G Arln allregulin decreases expression ISO Bortezomib results in decreased expression of ARLN mRNA CTD PMID:20977926 NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:211,055,911...211,057,681 		JBrowse link
G Arrb1 arrestin, beta 1 decreases expression ISO Bortezomib results in decreased expression of ARRB1 mRNA CTD PMID:20977926 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061 		JBrowse link
G Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 decreases expression ISO Bortezomib results in decreased expression of ASAP1 mRNA CTD PMID:20977926 NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754 		JBrowse link
G Ate1 arginyltransferase 1 increases expression ISO Bortezomib results in increased expression of ATE1 mRNA CTD PMID:20977926 NCBI chr 1:184,961,548...185,081,112
Ensembl chr 1:184,963,562...185,080,908 		JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression		 ISO pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA		 CTD PMID:12393500 PMID:20977926 NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236 		JBrowse link
G Atf3 activating transcription factor 3 increases response to substance
increases expression
multiple interactions		 ISO
EXP		 ATF3 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]		 CTD PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
decreases response to substance		 ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:16928686 PMID:20022965 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf5 activating transcription factor 5 increases expression ISO Bortezomib results in increased expression of ATF5 mRNA CTD PMID:17898295 NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707 		JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:22842577 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Atm ATM serine/threonine kinase multiple interactions
increases cleavage		 ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] CTD PMID:12393500 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437 		JBrowse link
G Atp1a3 ATPase Na+/K+ transporting subunit alpha 3 decreases expression ISO Bortezomib results in decreased expression of ATP1A3 mRNA CTD PMID:20977926 NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918 		JBrowse link
G Atp2a1 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 multiple interactions
affects response to substance		 ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib		 CTD PMID:25576094 NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838 		JBrowse link
G Atp6v0e1 ATPase H+ transporting V0 subunit e1 increases expression ISO Bortezomib results in increased expression of ATP6V0E1 mRNA CTD PMID:20977926 NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434 		JBrowse link
G B2m beta-2 microglobulin decreases expression ISO Bortezomib results in decreased expression of B2M protein CTD PMID:17204182 NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766 		JBrowse link
G B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of B3GNT2 mRNA CTD PMID:20977926 NCBI chr14:96,808,473...96,833,674
Ensembl chr14:96,806,664...96,835,273 		JBrowse link
G B4galt6 beta-1,4-galactosyltransferase 6 increases expression ISO Bortezomib results in increased expression of B4GALT6 mRNA CTD PMID:20977926 NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247 		JBrowse link
G Bag3 BAG cochaperone 3 increases expression ISO Bortezomib results in increased expression of BAG3 mRNA CTD PMID:15509775 PMID:17659339 PMID:20471514 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression		 ISO [nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein		 CTD PMID:12902978 PMID:17326159 PMID:20850924 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264 		JBrowse link
G Bard1 BRCA1 associated RING domain 1 increases response to substance ISO BARD1 mutant form results in increased susceptibility to Bortezomib CTD PMID:25522274 NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression		 ISO [Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein		 CTD PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression ISO Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein CTD PMID:17898295 PMID:20051518 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bbln bublin coiled coil protein decreases expression ISO Bortezomib results in decreased expression of BBLN mRNA CTD PMID:20977926 NCBI chr 3:15,674,577...15,677,322
Ensembl chr 3:15,674,580...15,677,374 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression
increases cleavage
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein		 CTD PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions
increases expression		 ISO [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein		 CTD PMID:18223231 PMID:20051518 NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance		 ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib		 CTD PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 More... NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression
increases activity
increases response to substance		 ISO [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib		 CTD PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 More... NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Bcl2l2 Bcl2-like 2 increases expression ISO Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624 		JBrowse link
G Bcl3 BCL3, transcription coactivator multiple interactions
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA		 CTD PMID:20471514 PMID:20977926 NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607 		JBrowse link
G Bcl6 BCL6, transcription repressor increases expression ISO Bortezomib results in increased expression of BCL6 mRNA CTD PMID:20977926 NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389 		JBrowse link
G Bcl7a BAF chromatin remodeling complex subunit BCL7A decreases expression ISO Bortezomib results in decreased expression of BCL7A mRNA CTD PMID:20977926 NCBI chr12:33,211,978...33,243,903
Ensembl chr12:33,223,931...33,243,886 		JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases expression ISO Bortezomib results in decreased expression of BCR mRNA CTD PMID:20977926 NCBI chr20:13,469,325...13,596,942
Ensembl chr20:13,471,668...13,597,016 		JBrowse link
G Becn1 beclin 1 multiple interactions
decreases response to substance		 ISO BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib		 CTD PMID:22842577 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Bid BH3 interacting domain death agonist increases cleavage
multiple interactions		 ISO Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]		 CTD PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 More... NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Bik BCL2-interacting killer increases response to substance
increases expression
increases activity		 ISO BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein		 CTD PMID:16446371 PMID:18566236 NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296 		JBrowse link
G Bin1 bridging integrator 1 increases expression ISO Bortezomib results in increased expression of BIN1 mRNA CTD PMID:17659339 NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263 		JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein		 CTD PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
increases expression
multiple interactions		 ISO Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA		 CTD PMID:17626072 PMID:24085292 PMID:25522274 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
increases expression		 ISO Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein]
Bortezomib results in increased expression of BIRC5 protein		 CTD PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 More... NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Birc7 baculoviral IAP repeat-containing 7 multiple interactions
decreases expression		 ISO arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] CTD PMID:21867610 NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606 		JBrowse link
G Bles03 basophilic leukemia expressed protein BLES03 decreases expression ISO Bortezomib results in decreased expression of C11ORF68 mRNA CTD PMID:20977926 NCBI chr 1:202,734,555...202,736,809
Ensembl chr 1:202,734,555...202,736,804 		JBrowse link
G Blk BLK proto-oncogene, Src family tyrosine kinase decreases expression ISO Bortezomib results in decreased expression of BLK mRNA CTD PMID:20977926 NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031 		JBrowse link
G Blvrb biliverdin reductase B increases expression ISO Bortezomib results in increased expression of BLVRB mRNA CTD PMID:20977926 NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375 		JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO Bortezomib results in increased expression of BNIP3 protein CTD PMID:20110775 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Brca1 BRCA1, DNA repair associated decreases expression
multiple interactions
increases response to substance
decreases ubiquitination		 ISO Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
Bortezomib results in decreased ubiquitination of BRCA1 protein		 CTD PMID:21917757 PMID:25522274 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304 		JBrowse link
G Brca2 BRCA2, DNA repair associated decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA		 CTD PMID:21917757 PMID:25913414 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567 		JBrowse link
G Brcc3 BRCA1/BRCA2-containing complex subunit 3 decreases expression ISO Bortezomib results in decreased expression of BRCC3 mRNA CTD PMID:20977926 NCBI chr 9:1,986,942...1,989,484
Ensembl chr 9:1,986,575...1,991,080 		JBrowse link
G Brf2 BRF2 general transcription factor 3B subunit increases expression ISO Bortezomib results in increased expression of BRF2 mRNA CTD PMID:20977926 NCBI chr16:64,928,334...64,933,057
Ensembl chr16:64,928,300...64,933,059 		JBrowse link
G Bsdc1 BSD domain containing 1 increases expression ISO Bortezomib results in increased expression of BSDC1 mRNA CTD PMID:20977926 NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092 		JBrowse link
G C17h6orf62 similar to human chromosome 6 open reading frame 62 increases expression ISO Bortezomib results in increased expression of C6ORF62 mRNA CTD PMID:20977926 NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020 		JBrowse link
G C1h9orf85 similar to human chromosome 9 open reading frame 85 increases expression ISO Bortezomib results in increased expression of C9ORF85 mRNA CTD PMID:20977926 NCBI chr 1:219,136,085...219,197,723
Ensembl chr 1:219,138,201...219,198,435 		JBrowse link
G C6h14orf132 similar to human chromosome 14 open reading frame 132 decreases expression ISO Bortezomib results in decreased expression of C14ORF132 mRNA CTD PMID:20977926 NCBI chr 6:124,365,466...124,398,449 JBrowse link
G Caap1 caspase activity and apoptosis inhibitor 1 increases expression ISO Bortezomib results in increased expression of CAAP1 mRNA CTD PMID:20977926 NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314 		JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H decreases degradation ISO Bortezomib results in decreased degradation of CACNA1H protein CTD PMID:30552955 NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376 		JBrowse link
G Calr calreticulin multiple interactions
increases expression		 ISO [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]		 CTD PMID:30482226 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414 		JBrowse link
G Capn15 calpain 15 decreases expression ISO Bortezomib results in decreased expression of CAPN15 mRNA CTD PMID:20977926 NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508 		JBrowse link
G Car9 carbonic anhydrase 9 decreases expression ISO Bortezomib results in decreased expression of CA9 protein CTD PMID:16061869 NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838 		JBrowse link
G Card9 caspase recruitment domain family, member 9 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA CTD PMID:20471514 NCBI chr 3:9,171,814...9,180,310
Ensembl chr 3:9,171,815...9,180,237 		JBrowse link
G Casp12 caspase 12 increases cleavage ISO Bortezomib results in increased cleavage of CASP12 protein CTD PMID:15509775 PMID:16357177 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037 		JBrowse link
G Casp2 caspase 2 multiple interactions
increases response to substance
increases cleavage		 ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein		 CTD PMID:15509775 PMID:16446371 PMID:18723477 NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379 		JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
multiple interactions
increases expression		 ISO Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
Bortezomib results in increased expression of CASP3 protein		 CTD PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp4 caspase 4 multiple interactions
increases response to substance
increases cleavage
increases activity		 ISO [Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein		 CTD PMID:16357177 PMID:18641367 NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092 		JBrowse link
G Casp6 caspase 6 multiple interactions
increases cleavage		 ISO Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] CTD PMID:16617327 PMID:17510429 NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502 		JBrowse link
G Casp7 caspase 7 multiple interactions
increases cleavage
increases activity		 ISO [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein		 CTD PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 More... NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage		 ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein] CTD PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 More... NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
increases response to substance
increases cleavage		 ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib		 CTD PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 More... NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase decreases expression
multiple interactions		 EXP Bortezomib results in decreased expression of CAT protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]		 CTD PMID:35121005 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbl Cbl proto-oncogene multiple interactions ISO [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] CTD PMID:19457607 NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176 		JBrowse link
G Cbr3 carbonyl reductase 3 increases expression ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA CTD PMID:20806931 PMID:20977926 NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875 		JBrowse link
G Cbx3 chromobox 3 increases expression ISO Bortezomib results in increased expression of CBX3 mRNA CTD PMID:20977926 NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283
Ensembl chr 4:80,546,010...80,559,283 		JBrowse link
G Ccar1 cell division cycle and apoptosis regulator 1 increases expression ISO Bortezomib results in increased expression of CCAR1 protein CTD PMID:21594647 PMID:21903591 NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526 		JBrowse link
G Ccdc186 coiled-coil domain containing 186 increases expression ISO Bortezomib results in increased expression of CCDC186 mRNA CTD PMID:20977926 NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935 		JBrowse link
G Ccdc32 coiled-coil domain containing 32 increases expression ISO Bortezomib results in increased expression of CCDC32 mRNA CTD PMID:20977926 NCBI chr 3:105,998,429...106,010,985
Ensembl chr 3:105,998,430...106,010,975 		JBrowse link
G Ccdc6 coiled-coil domain containing 6 decreases expression ISO Bortezomib results in decreased expression of CCDC6 mRNA CTD PMID:20977926 NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658 		JBrowse link
G Ccdc82 coiled-coil domain containing 82 increases expression ISO Bortezomib results in increased expression of CCDC82 mRNA CTD PMID:20977926 NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Bortezomib results in decreased expression of CCL2 mRNA CTD PMID:20471514 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression
decreases expression		 EXP
ISO		 Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA		 CTD PMID:18089816 PMID:20830808 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions
increases expression		 ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein		 CTD PMID:19074855 PMID:20367638 PMID:25522274 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein] CTD PMID:12893773 PMID:15173093 PMID:15781649 PMID:24333736 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO Bortezomib results in decreased expression of CCND2 mRNA CTD PMID:20977926 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495 		JBrowse link
G Ccnf cyclin F multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA CTD PMID:25522274 NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101 		JBrowse link
G Ccng2 cyclin G2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA CTD PMID:25522274 NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830 		JBrowse link
G Ccpg1 cell cycle progression 1 increases expression ISO Bortezomib results in increased expression of CCPG1 mRNA CTD PMID:20471514 PMID:20977926 NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430 		JBrowse link
G Cd27 CD27 molecule increases expression ISO Bortezomib results in increased expression of CD27 mRNA CTD PMID:17895889 NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592 		JBrowse link
G Cd38 CD38 molecule decreases expression ISO Bortezomib results in decreased expression of CD38 mRNA CTD PMID:20977926 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986 		JBrowse link
G Cd5 Cd5 molecule decreases expression ISO Bortezomib results in decreased expression of CD5 mRNA CTD PMID:20977926 NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313 		JBrowse link
G Cd69 Cd69 molecule increases expression ISO Bortezomib results in increased expression of CD69 mRNA CTD PMID:20977926 NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542 		JBrowse link
G Cd79a CD79a molecule decreases expression ISO Bortezomib results in decreased expression of CD79A mRNA CTD PMID:20977926 NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935 		JBrowse link
G Cd82 Cd82 molecule decreases expression ISO Bortezomib results in decreased expression of CD82 mRNA CTD PMID:20977926 NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809 		JBrowse link
G Cd9 CD9 molecule increases expression ISO Bortezomib results in increased expression of CD9 mRNA CTD PMID:20977926 NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222 		JBrowse link
G Cdc23 cell division cycle 23 increases expression ISO Bortezomib results in increased expression of CDC23 mRNA CTD PMID:20977926 NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163 		JBrowse link
G Cdc34 cell division cycle 34, ubiqiutin conjugating enzyme increases expression ISO Bortezomib results in increased expression of CDC34 mRNA CTD PMID:20977926 NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186 		JBrowse link
G Cdc37 cell division cycle 37, HSP90 cochaperone increases expression ISO Bortezomib results in increased expression of CDC37 mRNA CTD PMID:17895889 NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809 		JBrowse link
G Cdc42 cell division cycle 42 decreases expression ISO Bortezomib results in decreased expression of CDC42 mRNA CTD PMID:20977926 NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111 		JBrowse link
G Cdc42se2 CDC42 small effector 2 decreases expression ISO Bortezomib results in decreased expression of CDC42SE2 mRNA CTD PMID:20977926 NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059
Ensembl chr 1:38,836,555...38,905,059 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
increases phosphorylation
increases activity
decreases activity		 ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein]
Bortezomib results in increased phosphorylation of CDK1 protein
Bortezomib results in increased activity of CDK1 protein
Bortezomib results in decreased activity of CDK1 protein		 CTD PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity		 ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein]
Bortezomib results in decreased activity of CDK2 protein		 CTD PMID:14749476 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases stability
multiple interactions
decreases response to substance
increases expression		 ISO Bortezomib results in increased stability of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel]
CDKN1A results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein		 CTD PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 More... NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases stability
increases expression		 ISO [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]
Bortezomib results in increased stability of CDKN1B protein		 CTD PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 More... NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 decreases expression ISO Bortezomib results in decreased expression of CDT1 mRNA CTD PMID:17659339 NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression
decreases expression		 ISO
EXP		 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib results in decreased expression of CEBPB mRNA		 CTD PMID:20471514 PMID:20830808 PMID:30482226 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473 		JBrowse link
G Cenpc centromere protein C increases expression ISO Bortezomib results in increased expression of CENPC mRNA CTD PMID:20977926 NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476 		JBrowse link
G Cep290 centrosomal protein 290 increases expression ISO Bortezomib results in increased expression of CEP290 mRNA CTD PMID:20977926 NCBI chr 7:35,310,071...35,399,388
Ensembl chr 7:35,310,199...35,399,392 		JBrowse link
G Cers2 ceramide synthase 2 multiple interactions ISO Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein] CTD PMID:34915026 NCBI chr 2:182,890,527...182,898,805
Ensembl chr 2:182,890,493...182,933,314 		JBrowse link
G Cers6 ceramide synthase 6 multiple interactions ISO Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] CTD PMID:34915026 NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases response to substance
decreases expression
increases expression		 ISO Bortezomib affects the expression of CFLAR protein
[Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]
CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib
Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein
Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form		 CTD PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 More... NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Cgref1 cell growth regulator with EF hand domain 1 increases expression ISO Bortezomib results in increased expression of CGREF1 mRNA CTD PMID:17895889 NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO Bortezomib results in increased expression of CHAC1 mRNA CTD PMID:15509775 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526 		JBrowse link
G Chaf1a chromatin assembly factor 1 subunit A decreases expression ISO Bortezomib results in decreased expression of CHAF1A mRNA CTD PMID:17659339 NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654 		JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 increases expression ISO Bortezomib results in increased expression of CHD2 mRNA CTD PMID:20977926 NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502 		JBrowse link
G Chfr checkpoint with forkhead and ring finger domains decreases expression ISO Bortezomib results in decreased expression of CHFR mRNA CTD PMID:20977926 NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014 		JBrowse link
G Chst11 carbohydrate sulfotransferase 11 decreases expression ISO Bortezomib results in decreased expression of CHST11 mRNA CTD PMID:20977926 NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111 		JBrowse link
G Chst2 carbohydrate sulfotransferase 2 decreases expression ISO Bortezomib results in decreased expression of CHST2 mRNA CTD PMID:20977926 NCBI chr 8:95,960,067...95,966,312
Ensembl chr 8:95,959,826...95,966,955 		JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases expression
increases activity		 ISO Bortezomib results in increased expression of CHUK mRNA
Bortezomib results in increased activity of CHUK protein		 CTD PMID:20471514 PMID:24085292 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065 		JBrowse link
G Cideb cell death-inducing DFFA-like effector b decreases expression ISO Bortezomib results in decreased expression of CIDEB mRNA CTD PMID:17659339 NCBI chr15:29,252,208...29,256,482
Ensembl chr15:29,252,213...29,256,605 		JBrowse link
G Cilk1 ciliogenesis associated kinase 1 increases expression ISO Bortezomib results in increased expression of CILK1 mRNA CTD PMID:20977926 NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691 		JBrowse link
G Clec7a C-type lectin domain containing 7A increases expression ISO Bortezomib results in increased expression of CLEC7A mRNA CTD PMID:20977926 NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897 		JBrowse link
G Clip4 CAP-GLY domain containing linker protein family, member 4 increases expression ISO Bortezomib results in increased expression of CLIP4 mRNA CTD PMID:20977926 NCBI chr 6:23,616,280...23,697,625
NCBI chr 6:23,718,580...23,729,231
NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874 		JBrowse link
G Cln6 CLN6, transmembrane ER protein decreases expression ISO Bortezomib results in decreased expression of CLN6 mRNA CTD PMID:20977926 NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360 		JBrowse link
G Clptm1 CLPTM1 regulator of GABA type A receptor forward trafficking decreases expression ISO Bortezomib results in decreased expression of CLPTM1 mRNA CTD PMID:20977926 NCBI chr 1:79,289,478...79,321,079
Ensembl chr 1:79,289,477...79,321,092 		JBrowse link
G Clu clusterin increases expression ISO Bortezomib results in increased expression of CLU mRNA CTD PMID:20977926 NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315 		JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO Bortezomib results in decreased expression of COX8A mRNA CTD PMID:30818834 NCBI chr 1:204,402,118...204,404,439 JBrowse link
G Cpt1c carnitine palmitoyltransferase 1c increases response to substance ISO CPT1C gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 decreases expression
multiple interactions		 EXP Bortezomib results in decreased expression of CREB1 protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein]		 CTD PMID:35121005 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816 		JBrowse link
G Crebbp CREB binding protein decreases expression ISO Bortezomib results in decreased expression of CREBBP mRNA CTD PMID:25913414 NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888 		JBrowse link
G Crem cAMP responsive element modulator increases expression ISO Bortezomib results in increased expression of CREM mRNA CTD PMID:20977926 NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989 		JBrowse link
G Crip2 cysteine-rich protein 2 decreases expression ISO Bortezomib results in decreased expression of CRIP2 mRNA CTD PMID:20977926 NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065 		JBrowse link
G Cripto cripto, EGF-CFC family member increases expression ISO Bortezomib results in increased expression of CRIPTO mRNA CTD PMID:17895889 NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308 		JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein CTD PMID:15039284 NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238 		JBrowse link
G Cryab crystallin, alpha B multiple interactions
increases expression		 ISO
EXP		 [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA
Bortezomib results in increased expression of CRYAB mRNA		 CTD PMID:20830808 PMID:25522274 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157 		JBrowse link
G Cst7 cystatin F increases expression ISO Bortezomib results in increased expression of CST7 mRNA CTD PMID:20977926 NCBI chr 3:139,396,830...139,405,557
Ensembl chr 3:139,396,850...139,405,557 		JBrowse link
G Ctdspl2 CTD small phosphatase like 2 decreases expression ISO Bortezomib results in decreased expression of CTDSPL2 mRNA CTD PMID:20977926 NCBI chr 3:108,915,263...108,970,620
Ensembl chr 3:108,915,280...108,967,227 		JBrowse link
G Cth cystathionine gamma-lyase multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA CTD PMID:25522274 NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases response to substance
increases expression		 ISO 2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] CTD PMID:18485479 PMID:19100720 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Ctsb cathepsin B multiple interactions
increases localization		 ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] CTD PMID:16446371 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500 		JBrowse link
G Ctsd cathepsin D increases expression ISO Bortezomib results in increased expression of CTSD mRNA CTD PMID:20977926 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488 		JBrowse link
G Cul1 cullin 1 increases expression ISO Bortezomib results in increased expression of CUL1 mRNA CTD PMID:17895889 NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980 		JBrowse link
G Cul3 cullin 3 decreases expression ISO Bortezomib results in decreased expression of CUL3 mRNA CTD PMID:17659339 NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462 		JBrowse link
G Cwf19l1 CWF19 like cell cycle control factor 1 decreases expression ISO Bortezomib results in decreased expression of CWF19L1 mRNA CTD PMID:20977926 NCBI chr 1:242,997,720...243,020,989
Ensembl chr 1:242,997,726...243,020,961 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression ISO Bortezomib results in increased expression of CXCL1 mRNA CTD PMID:15509775 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions		 ISO
EXP		 Bortezomib results in increased expression of CXCL2 mRNA
Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]		 CTD PMID:20830808 PMID:27194111 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
increases expression		 ISO Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA]
Bortezomib results in increased expression of CXCL1 mRNA		 CTD PMID:15509775 PMID:27194111 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO Bortezomib results in decreased expression of CXCR4 mRNA CTD PMID:20977926 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883 		JBrowse link
G Cyb5r1 cytochrome b5 reductase 1 increases expression ISO Bortezomib results in increased expression of CYB5R1 mRNA CTD PMID:20977926 NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458 		JBrowse link
G Cyba cytochrome b-245 alpha chain decreases expression ISO Bortezomib results in decreased expression of CYBA mRNA CTD PMID:20977926 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions
affects localization		 ISO [Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein
Bortezomib affects the localization of CYCS protein		 CTD PMID:12893773 PMID:16024631 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects metabolic processing ISO CYP1A2 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 affects metabolic processing ISO CYP2C19 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO Bortezomib results in increased expression of CYP2U1 mRNA CTD PMID:20977926 NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects metabolic processing ISO CYP3A4 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cytip cytohesin 1 interacting protein increases expression ISO Bortezomib results in increased expression of CYTIP mRNA CTD PMID:20977926 NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993 		JBrowse link
G Dap3 death associated protein 3 increases expression ISO Bortezomib results in increased expression of DAP3 mRNA CTD PMID:17659339 NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461 		JBrowse link
G Dapk2 death-associated protein kinase 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA CTD PMID:25522274 NCBI chr 8:66,706,536...66,825,567
Ensembl chr 8:66,706,609...66,825,567 		JBrowse link
G Dazap2 DAZ associated protein 2 decreases expression ISO Bortezomib results in decreased expression of DAZAP2 mRNA CTD PMID:20977926 NCBI chr 7:131,714,749...131,720,266
Ensembl chr 7:131,714,745...131,720,265 		JBrowse link
G Dbn1 drebrin 1 increases expression ISO Bortezomib results in increased expression of DBN1 mRNA CTD PMID:20977926 NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984 		JBrowse link
G Dcaf11 DDB1 and CUL4 associated factor 11 decreases expression ISO Bortezomib results in decreased expression of DCAF11 mRNA CTD PMID:20977926 NCBI chr15:29,046,744...29,057,450
Ensembl chr15:29,046,826...29,057,669 		JBrowse link
G Dcaf13 DDB1 and CUL4 associated factor 13 increases expression ISO Bortezomib results in increased expression of DCAF13 mRNA CTD PMID:20977926 NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142 		JBrowse link
G Dcps decapping enzyme, scavenger decreases expression ISO Bortezomib results in decreased expression of DCPS mRNA CTD PMID:20977926 NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
decreases response to substance		 ISO
EXP		 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]
Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]
DDIT3 results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 More... NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Ddx11 DEAD/H-box helicase 11 decreases expression ISO Bortezomib results in decreased expression of DDX11 mRNA CTD PMID:20977926 NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550 		JBrowse link
G Deaf1 DEAF1 transcription factor decreases expression ISO Bortezomib results in decreased expression of DEAF1 mRNA CTD PMID:20977926 NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541 		JBrowse link
G Dedd2 death effector domain containing 2 increases expression ISO Bortezomib results in increased expression of DEDD2 mRNA CTD PMID:17659339 NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714 		JBrowse link
G Def6 DEF6 guanine nucleotide exchange factor decreases expression ISO Bortezomib results in decreased expression of DEF6 mRNA CTD PMID:20977926 NCBI chr20:6,268,579...6,290,030
Ensembl chr20:6,268,601...6,289,961 		JBrowse link
G Dennd4a DENN domain containing 4A increases expression ISO Bortezomib results in increased expression of DENND4A mRNA CTD PMID:20977926 NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330 		JBrowse link
G Dennd4b DENN domain containing 4B increases expression ISO Bortezomib results in increased expression of DENND4B mRNA CTD PMID:15509775 NCBI chr 2:175,720,473...175,736,425
Ensembl chr 2:175,709,610...175,736,426 		JBrowse link
G Dennd4c DENN domain containing 4C increases expression ISO Bortezomib results in increased expression of DENND4C mRNA CTD PMID:20977926 NCBI chr 5:101,272,298...101,369,529
Ensembl chr 5:101,272,005...101,368,118 		JBrowse link
G Dgke diacylglycerol kinase epsilon decreases expression ISO Bortezomib results in decreased expression of DGKE mRNA CTD PMID:20977926 NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100 		JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
increases localization
increases expression
multiple interactions		 ISO Bortezomib affects the localization of DIABLO protein
Bortezomib results in increased localization of DIABLO protein
Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]		 CTD PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 More... NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387 		JBrowse link
G Dlgap5 DLG associated protein 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA CTD PMID:25522274 NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518 		JBrowse link
G Dnaaf5 dynein, axonemal, assembly factor 5 decreases expression ISO Bortezomib results in decreased expression of DNAAF5 mRNA CTD PMID:20977926 NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO Bortezomib results in increased expression of DNAJB1 mRNA CTD PMID:15509775 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajc14 DnaJ heat shock protein family (Hsp40) member C14 decreases expression ISO Bortezomib results in decreased expression of DNAJC14 mRNA CTD PMID:20977926 NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645 		JBrowse link
G Dnajc4 DnaJ heat shock protein family (Hsp40) member C4 decreases expression ISO Bortezomib results in decreased expression of DNAJC4 mRNA CTD PMID:20977926 NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387 		JBrowse link
G Dnm2 dynamin 2 decreases expression ISO Bortezomib results in decreased expression of DNM2 mRNA CTD PMID:20977926 NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157 		JBrowse link
G Dpy19l4 dpy-19 like 4 increases expression ISO Bortezomib results in increased expression of DPY19L4 mRNA CTD PMID:20977926 NCBI chr 5:24,351,289...24,410,932
Ensembl chr 5:24,353,900...24,410,912 		JBrowse link
G Dst dystonin increases expression ISO Bortezomib results in increased expression of DST mRNA CTD PMID:17659339 NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615 		JBrowse link
G Dusp15 dual specificity phosphatase 15 decreases expression ISO Bortezomib results in decreased expression of DUSP15 mRNA CTD PMID:20977926 NCBI chr 3:141,408,495...141,419,137
Ensembl chr 3:141,408,498...141,418,999 		JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression ISO Bortezomib results in decreased expression of DUSP4 mRNA CTD PMID:20977926 NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138 		JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA CTD PMID:25522274 NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818 		JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 increases expression ISO Bortezomib results in increased expression of DYNC1I1 mRNA CTD PMID:20977926 NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149 		JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein CTD PMID:25522274 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361 		JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold increases expression ISO Bortezomib results in increased expression of ECPAS mRNA CTD PMID:20977926 NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860 		JBrowse link
G Edaradd EDAR associated via death domain increases expression ISO Bortezomib results in increased expression of EDARADD mRNA CTD PMID:17895889 NCBI chr17:85,866,629...85,910,612
Ensembl chr17:85,656,905...85,910,447 		JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA CTD PMID:25522274 NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766 		JBrowse link
G Egr1 early growth response 1 increases expression ISO Bortezomib results in increased expression of EGR1 mRNA CTD PMID:20471514 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Egr2 early growth response 2 decreases expression ISO
EXP		 Bortezomib results in decreased expression of EGR2 mRNA
Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein		 CTD PMID:20830808 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562 		JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of EHMT2 mRNA CTD PMID:20977926 NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547 		JBrowse link
G Eif1 eukaryotic translation initiation factor 1 increases expression ISO Bortezomib results in increased expression of EIF1 mRNA CTD PMID:20977926 NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
Ensembl chr 5:85,246,764...85,427,327 		JBrowse link
G Eif2a eukaryotic translation initiation factor 2A decreases phosphorylation ISO Bortezomib results in decreased phosphorylation of EIF2A protein CTD PMID:18641367 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases phosphorylation
multiple interactions
decreases response to substance		 ISO Bortezomib results in increased phosphorylation of EIF2AK3 protein
Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]
Bortezomib promotes the reaction [ricolinostat results in increased phosphorylation of EIF2AK3 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
EIF2AK3 results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:16928686 PMID:20022965 PMID:22262760 PMID:22959925 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions
increases phosphorylation		 ISO Bortezomib affects the reaction [ricolinostat results in increased phosphorylation of EIF2S1 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] CTD PMID:16357177 PMID:20022965 PMID:21090173 PMID:22262760 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Eif2s3 eukaryotic translation initiation factor 2 subunit gamma decreases expression ISO Bortezomib results in decreased expression of EIF2S3 mRNA CTD PMID:20977926 NCBI chr  X:58,916,513...58,939,923
Ensembl chr  X:58,917,490...58,940,686 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:21345073 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984 		JBrowse link
G Eif5a eukaryotic translation initiation factor 5A decreases expression ISO Bortezomib results in decreased expression of EIF5A mRNA CTD PMID:20977926 NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656 		JBrowse link
G Elp5 elongator acetyltransferase complex subunit 5 decreases expression ISO Bortezomib results in decreased expression of ELP5 mRNA CTD PMID:20977926 NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923 		JBrowse link
G Eno2 enolase 2 increases expression ISO Bortezomib results in increased expression of ENO2 mRNA CTD PMID:20977926 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980 		JBrowse link
G Epha1 Eph receptor A1 decreases expression ISO Bortezomib results in decreased expression of EPHA1 mRNA CTD PMID:20977926 NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846 		JBrowse link
G Ephb2 Eph receptor B2 decreases expression ISO Bortezomib results in decreased expression of EPHB2 mRNA CTD PMID:20977926 NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation		 ISO Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] CTD PMID:20701607 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Ercc3 ERCC excision repair 3, TFIIH core complex helicase subunit increases response to substance ISO ERCC3 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329 		JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit increases response to substance ISO ERCC4 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
Ensembl chr10:2,419,038...2,448,369 		JBrowse link
G Erlin2 ER lipid raft associated 2 decreases expression ISO Bortezomib results in decreased expression of ERLIN2 mRNA CTD PMID:20977926 NCBI chr16:65,017,654...65,034,184
Ensembl chr16:65,018,532...65,033,671 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
decreases response to substance		 ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; Bortezomib affects the reaction [ricolinostat affects the phosphorylation of ERN1 protein]
ERN1 results in decreased susceptibility to Bortezomib		 CTD PMID:16357177 PMID:22262760 PMID:25522274 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Esf1 ESF1 nucleolar pre-rRNA processing protein homolog increases expression ISO Bortezomib results in increased expression of ESF1 mRNA CTD PMID:20977926 NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:25752796 PMID:30818834 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] CTD PMID:25752796 PMID:25913414 PMID:30818834 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919 		JBrowse link
G Esrra estrogen related receptor, alpha decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of ESRRA mRNA
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]		 CTD PMID:20977926 PMID:30818834 NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268 		JBrowse link
G Esyt2 extended synaptotagmin 2 decreases expression ISO Bortezomib results in decreased expression of ESYT2 mRNA CTD PMID:20977926 NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590 		JBrowse link
G Etv4 ETS variant transcription factor 4 decreases expression ISO Bortezomib results in decreased expression of ETV4 mRNA CTD PMID:20977926 NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974 		JBrowse link
G F2rl1 F2R like trypsin receptor 1 decreases expression ISO Bortezomib results in decreased expression of F2RL1 mRNA CTD PMID:20977926 NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226 		JBrowse link
G F3 coagulation factor III, tissue factor increases expression
multiple interactions		 ISO Bortezomib results in increased expression of F3 protein
[Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein		 CTD PMID:23696885 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668 		JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO Bortezomib results in decreased expression of FADS2 mRNA CTD PMID:20977926 NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789 		JBrowse link
G Faf1 Fas associated factor 1 increases expression ISO Bortezomib results in increased expression of FAF1 mRNA CTD PMID:17895889 NCBI chr 5:124,426,032...124,790,014
Ensembl chr 5:124,426,062...124,789,977 		JBrowse link
G Fam118b family with sequence similarity 118, member B increases expression ISO Bortezomib results in increased expression of FAM118B mRNA CTD PMID:20977926 NCBI chr 8:33,566,681...33,617,310
Ensembl chr 8:33,566,669...33,617,270 		JBrowse link
G Fam168a family with sequence similarity 168, member A increases expression ISO Bortezomib results in increased expression of FAM168A mRNA CTD PMID:20977926 NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220 		JBrowse link
G Fam20b FAM20B, glycosaminoglycan xylosylkinase decreases expression ISO Bortezomib results in decreased expression of FAM20B mRNA CTD PMID:20977926 NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915 		JBrowse link
G Fam219a family with sequence similarity 219, member A increases expression ISO Bortezomib results in increased expression of FAM219A mRNA CTD PMID:20977926 NCBI chr 5:56,679,272...56,729,959
Ensembl chr 5:56,680,613...56,729,924 		JBrowse link
G Fam241b family with sequence similarity 241 member B increases expression ISO Bortezomib results in increased expression of FAM241B mRNA CTD PMID:20977926 NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
Ensembl chr 6:30,052,324...30,055,084 		JBrowse link
G Fam43a family with sequence similarity 43, member A decreases expression ISO Bortezomib results in decreased expression of FAM43A mRNA CTD PMID:20977926 NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401 		JBrowse link
G Fam76a family with sequence similarity 76, member A increases expression ISO Bortezomib results in increased expression of FAM76A mRNA CTD PMID:20977926 NCBI chr 5:145,107,491...145,135,734
Ensembl chr 5:145,107,491...145,135,574 		JBrowse link
G Fancd2 FA complementation group D2 decreases expression ISO Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein CTD PMID:19934314 PMID:21917757 NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412 		JBrowse link
G Farsa phenylalanyl-tRNA synthetase subunit alpha decreases expression ISO Bortezomib results in decreased expression of FARSA mRNA CTD PMID:20977926 NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions
decreases expression
increases expression		 ISO [Bortezomib co-treated with vorinostat] results in increased expression of FAS protein
Bortezomib results in decreased expression of FAS mRNA
Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein		 CTD PMID:17351739 PMID:20471514 PMID:25913414 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Faslg Fas ligand multiple interactions
increases expression		 ISO [Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein]
Bortezomib results in increased expression of FASLG protein		 CTD PMID:17351739 PMID:20471514 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Fastk Fas-activated serine/threonine kinase decreases expression ISO Bortezomib results in decreased expression of FASTK mRNA CTD PMID:20977926 NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430 		JBrowse link
G Fbln5 fibulin 5 decreases expression ISO Bortezomib results in decreased expression of FBLN5 mRNA CTD PMID:20977926 NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755 		JBrowse link
G Fbxw7 F-box and WD repeat domain containing 7 decreases expression ISO Bortezomib results in decreased expression of FBXW7 mRNA CTD PMID:20977926 NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941 		JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA CTD PMID:25522274 NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454 		JBrowse link
G Fgfr1op2 FGFR1 oncogene partner 2 increases expression ISO Bortezomib results in increased expression of FGFR1OP2 mRNA CTD PMID:20977926 NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630 		JBrowse link
G Fkbp1a FKBP prolyl isomerase 1A decreases expression ISO Bortezomib results in decreased expression of FKBP1A mRNA CTD PMID:20977926 NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 decreases expression ISO Bortezomib results in decreased expression of FKBP5 mRNA CTD PMID:20977926 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Flcn folliculin increases expression ISO Bortezomib results in increased expression of FLCN mRNA CTD PMID:20977926 NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769 		JBrowse link
G Fmr1 fragile X messenger ribonucleoprotein 1 decreases expression ISO Bortezomib results in decreased expression of FMR1 mRNA CTD PMID:17659339 NCBI chr  X:147,240,239...147,278,057
Ensembl chr  X:147,240,301...147,278,050 		JBrowse link
G Folr1 folate receptor alpha decreases expression ISO Bortezomib results in decreased expression of FOLR1 mRNA CTD PMID:20977926 NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667 		JBrowse link
G Foxa1 forkhead box A1 multiple interactions
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA
Bortezomib results in decreased expression of FOXA1 mRNA		 CTD PMID:20471514 PMID:25913414 NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188 		JBrowse link
G Fry FRY microtubule binding protein increases expression ISO Bortezomib results in increased expression of FRY mRNA CTD PMID:20977926 NCBI chr12:4,493,890...4,887,118
Ensembl chr12:4,493,891...4,799,116 		JBrowse link
G Fsd1l fibronectin type III and SPRY domain containing 1-like increases expression ISO Bortezomib results in increased expression of FSD1L mRNA CTD PMID:20977926 NCBI chr 5:68,258,877...68,334,931
Ensembl chr 5:68,258,932...68,334,928 		JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA CTD PMID:25522274 NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases expression ISO Bortezomib results in decreased expression of G6PD mRNA CTD PMID:20977926 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801 		JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression ISO Bortezomib results in increased expression of GABARAPL1 mRNA CTD PMID:20977926 NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
multiple interactions		 ISO
EXP		 Bortezomib results in increased expression of GADD45A mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA		 CTD PMID:20830808 PMID:20977926 PMID:25522274 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions		 ISO Bortezomib results in increased expression of GADD45B mRNA
Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]		 CTD PMID:15509775 PMID:15797874 PMID:17895889 PMID:17898295 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046 		JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma increases expression ISO Bortezomib results in increased expression of GADD45G mRNA CTD PMID:17898295 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610 		JBrowse link
G Galnt4 polypeptide N-acetylgalactosaminyltransferase 4 increases expression ISO Bortezomib results in increased expression of GALNT4 mRNA CTD PMID:20977926 NCBI chr 7:33,925,229...33,927,770 JBrowse link
G Ganab glucosidase II alpha subunit decreases expression ISO Bortezomib results in decreased expression of GANAB mRNA CTD PMID:20977926 NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695 		JBrowse link
G Gas7 growth arrest specific 7 decreases expression ISO Bortezomib results in decreased expression of GAS7 mRNA CTD PMID:20977926 NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276 		JBrowse link
G Gbp2 guanylate binding protein 2 increases expression ISO Bortezomib results in increased expression of GBP2 mRNA CTD PMID:20977926 NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions		 EXP Bortezomib results in increased expression of GCLC mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA]		 CTD PMID:35121005 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions		 EXP Bortezomib results in increased expression of GCLM mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA]		 CTD PMID:35121005 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 increases expression ISO Bortezomib results in increased expression of GCNT2 mRNA CTD PMID:20977926 NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611 		JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions		 EXP
ISO		 Bortezomib results in increased expression of GDF15 mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA		 CTD PMID:20830808 PMID:25522274 NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions
increases expression		 EXP Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] CTD PMID:35121005 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Ghr growth hormone receptor increases expression ISO Bortezomib results in increased expression of GHR mRNA CTD PMID:17895889 NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735 		JBrowse link
G Git1 GIT ArfGAP 1 decreases expression ISO Bortezomib results in decreased expression of GIT1 mRNA CTD PMID:20977926 NCBI chr10:62,342,082...62,356,379
Ensembl chr10:62,342,299...62,356,373 		JBrowse link
G Gkap1 G kinase anchoring protein 1 increases expression ISO Bortezomib results in increased expression of GKAP1 mRNA CTD PMID:20977926 NCBI chr17:6,383,963...6,423,684
Ensembl chr17:6,383,963...6,423,679 		JBrowse link
G Gla galactosidase, alpha increases expression ISO Bortezomib results in increased expression of GLA mRNA CTD PMID:20977926 NCBI chr  X:97,769,227...97,780,646
Ensembl chr  X:97,768,996...97,780,664 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
increases expression		 ISO TERT protein inhibits the reaction [Bortezomib results in increased expression of GLB1 protein] CTD PMID:36401358 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127 		JBrowse link
G Gnai3 G protein subunit alpha i3 increases expression ISO Bortezomib results in increased expression of GNAI3 mRNA CTD PMID:20977926 NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742 		JBrowse link
G Gosr2 golgi SNAP receptor complex member 2 increases expression ISO Bortezomib results in increased expression of GOSR2 mRNA CTD PMID:20977926 NCBI chr10:88,585,291...88,605,642
Ensembl chr10:88,586,299...88,605,625 		JBrowse link
G Gpank1 G patch domain and ankyrin repeats 1 increases expression ISO Bortezomib results in increased expression of GPANK1 mRNA CTD PMID:20977926 NCBI chr20:3,697,641...3,700,814
Ensembl chr20:3,697,641...3,700,858 		JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 increases expression ISO Bortezomib results in increased expression of GPAT3 mRNA CTD PMID:20977926 NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490 		JBrowse link
G Gpatch2l G patch domain containing 2-like increases expression ISO Bortezomib results in increased expression of GPATCH2L mRNA CTD PMID:20977926 NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888 		JBrowse link
G Gphn gephyrin decreases expression ISO Bortezomib results in decreased expression of GPHN mRNA CTD PMID:20977926 NCBI chr 6:96,954,365...97,483,617
Ensembl chr 6:96,892,148...97,483,612 		JBrowse link
G Gpr157 G protein-coupled receptor 157 decreases expression ISO Bortezomib results in decreased expression of GPR157 mRNA CTD PMID:20977926 NCBI chr 5:160,550,703...160,566,432
Ensembl chr 5:160,550,713...160,566,432 		JBrowse link
G Gpsm3 G-protein signaling modulator 3 decreases expression ISO Bortezomib results in decreased expression of GPSM3 mRNA CTD PMID:20977926 NCBI chr20:4,157,123...4,158,984
Ensembl chr20:4,157,123...4,159,035 		JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form CTD PMID:16118318 NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein] CTD PMID:16118318 PMID:24085292 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gspt1 G1 to S phase transition 1 decreases expression ISO Bortezomib results in decreased expression of GSPT1 mRNA CTD PMID:20977926 NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198 		JBrowse link
G Gsr glutathione-disulfide reductase increases expression ISO Bortezomib results in increased expression of GSR mRNA CTD PMID:20977926 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Gstcd glutathione S-transferase, C-terminal domain containing decreases expression ISO Bortezomib results in decreased expression of GSTCD mRNA CTD PMID:20977926 NCBI chr 2:221,499,732...221,591,888
Ensembl chr 2:221,499,083...221,591,857 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 decreases expression ISO Bortezomib results in decreased expression of GSTM4 mRNA CTD PMID:20977926 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323 		JBrowse link
G Gtf3c2 general transcription factor IIIC subunit 2 decreases expression ISO Bortezomib results in decreased expression of GTF3C2 mRNA CTD PMID:20977926 NCBI chr 6:25,196,439...25,221,338
Ensembl chr 6:25,197,268...25,220,490 		JBrowse link
G Gtpbp1 GTP binding protein 1 decreases expression ISO Bortezomib results in decreased expression of GTPBP1 mRNA CTD PMID:20977926 NCBI chr 7:111,248,254...111,272,705
Ensembl chr 7:111,248,254...111,272,705 		JBrowse link
G Gzma granzyme A decreases expression ISO Bortezomib results in decreased expression of GZMA mRNA CTD PMID:20977926 NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493 		JBrowse link
G Gzmb granzyme B increases expression ISO Bortezomib results in increased expression of GZMB mRNA CTD PMID:20977926 NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814 		JBrowse link
G H2ax H2A.X variant histone multiple interactions
decreases phosphorylation
increases expression		 ISO
EXP		 [Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form]
Bortezomib results in decreased phosphorylation of H2AX protein
Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]		 CTD PMID:15173094 PMID:16778179 PMID:17875725 PMID:18790767 PMID:32482060 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239 		JBrowse link
G H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) decreases expression ISO Bortezomib results in decreased expression of H6PD mRNA CTD PMID:20977926 NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171 		JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha increases expression ISO Bortezomib results in increased expression of HADHA mRNA CTD PMID:20977926 NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869 		JBrowse link
G Haus6 HAUS augmin like complex subunit 6 increases expression ISO Bortezomib results in increased expression of HAUS6 mRNA CTD PMID:20977926 NCBI chr 5:101,116,532...101,156,396
Ensembl chr 5:101,119,300...101,153,124 		JBrowse link
G Hdac10 histone deacetylase 10 decreases expression ISO Bortezomib results in decreased expression of HDAC10 mRNA CTD PMID:20977926 NCBI chr 7:120,199,126...120,205,850
Ensembl chr 7:120,199,129...120,204,228 		JBrowse link
G Hdac4 histone deacetylase 4 decreases expression ISO Bortezomib results in decreased expression of HDAC4 mRNA CTD PMID:17659339 NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164 		JBrowse link
G Hdac6 histone deacetylase 6 decreases response to substance ISO HDAC6 results in decreased susceptibility to Bortezomib CTD PMID:16585204 NCBI chr  X:14,550,645...14,572,445
Ensembl chr  X:14,551,044...14,572,441 		JBrowse link
G Hectd2 HECT domain E3 ubiquitin protein ligase 2 increases expression ISO Bortezomib results in increased expression of HECTD2 mRNA CTD PMID:20977926 NCBI chr 1:234,274,967...234,345,598
Ensembl chr 1:234,275,705...234,343,487 		JBrowse link
G Hecw1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA CTD PMID:25522274 NCBI chr17:50,671,239...51,084,536
Ensembl chr17:50,670,954...51,080,720 		JBrowse link
G Hexd hexosaminidase D decreases expression ISO Bortezomib results in decreased expression of HEXD mRNA CTD PMID:20977926 NCBI chr10:106,479,781...106,498,799
Ensembl chr10:106,480,194...106,498,799 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO Bortezomib results in increased expression of HIF1A protein CTD PMID:16061869 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hikeshi heat shock protein nuclear import factor hikeshi multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA CTD PMID:25522274 NCBI chr 1:143,825,399...143,849,361
Ensembl chr 1:143,825,923...143,849,363 		JBrowse link
G Hist1h2ail1 histone cluster 1 H2a family member I like 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA CTD PMID:25522274 NCBI chr17:41,568,181...41,569,093
Ensembl chr17:41,568,471...41,569,109 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
increases response to substance		 ISO
EXP		 [arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
HMOX1 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein		 CTD PMID:15509775 PMID:17895889 PMID:19417023 PMID:20471514 PMID:25913414 More... NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hmox2 heme oxygenase 2 multiple interactions ISO abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA] CTD PMID:19417023 NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148 		JBrowse link
G Hnrnpll heterogeneous nuclear ribonucleoprotein L-like increases expression ISO Bortezomib results in increased expression of HNRNPLL mRNA CTD PMID:20977926 NCBI chr 6:14,969,953...15,000,574
Ensembl chr 6:14,970,057...14,999,745 		JBrowse link
G Hoxa11 homeobox A11 decreases expression ISO Bortezomib results in decreased expression of HOXA11 mRNA CTD PMID:20977926 NCBI chr 4:81,342,527...81,346,189
Ensembl chr 4:81,342,528...81,346,232 		JBrowse link
G Hps3 HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 decreases expression ISO Bortezomib results in decreased expression of HPS3 mRNA CTD PMID:20977926 NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22842577 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hsf1 heat shock transcription factor 1 increases expression
increases activity
multiple interactions		 ISO Bortezomib results in increased expression of HSF1 mRNA
Bortezomib results in increased activity of HSF1 protein
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]		 CTD PMID:17895889 PMID:23874968 PMID:24619424 PMID:31540997 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011 		JBrowse link
G Hsf2 heat shock transcription factor 2 increases expression
multiple interactions		 ISO Bortezomib results in increased expression of HSF2 mRNA; Bortezomib results in increased expression of HSF2 protein
HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein]		 CTD PMID:24619424 NCBI chr20:36,819,864...36,847,490
Ensembl chr20:36,819,864...36,850,174 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases expression
decreases expression		 ISO
EXP		 Bortezomib results in increased expression of HSP90AA1 mRNA
Bortezomib results in decreased expression of HSP90AA1 mRNA		 CTD PMID:17895889 PMID:20471514 PMID:20830808 NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268 		JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 increases expression ISO Bortezomib results in increased expression of HSP90AB1 mRNA CTD PMID:17895889 NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions
decreases response to substance
increases expression		 ISO Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]
HSPA1A protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA1A mRNA		 CTD PMID:17895889 PMID:23874968 NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227 		JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B increases expression
affects response to substance
decreases response to substance		 ISO Bortezomib results in increased expression of HSPA1B mRNA
HSPA1B protein affects the susceptibility to Bortezomib
HSPA1B protein results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:17895889 PMID:23874968 NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240 		JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression EXP Bortezomib results in increased expression of HSPA4L mRNA CTD PMID:20830808 NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression
decreases response to substance		 ISO Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]
Bortezomib results in increased expression of HSPA5 mRNA
HSPA5 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein		 CTD PMID:15141013 PMID:15509775 PMID:16024631 PMID:16357177 PMID:18641367 More... NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspa6l-ps1 heat shock protein family A (Hsp70) member 6 like, pseudogene 1 increases expression ISO Bortezomib results in increased expression of HSPA6 mRNA CTD PMID:15509775 PMID:17898295 PMID:20977926 NCBI chr13:83,273,176...83,274,317 JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression
decreases response to substance		 EXP
ISO		 Bortezomib results in increased expression of HSPB1 mRNA
HSPB1 protein results in decreased susceptibility to Bortezomib		 CTD PMID:14559800 PMID:20830808 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743 		JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 increases expression ISO Bortezomib results in increased expression of HSPH1 mRNA CTD PMID:17898295 NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224 		JBrowse link
G Htr2b 5-hydroxytryptamine receptor 2B decreases expression ISO Bortezomib results in decreased expression of HTR2B mRNA CTD PMID:20977926 NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108 		JBrowse link
G Htra2 HtrA serine peptidase 2 affects localization ISO Bortezomib affects the localization of HTRA2 protein CTD PMID:16024631 NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095 		JBrowse link
G Ibtk inhibitor of Bruton tyrosine kinase increases expression ISO Bortezomib results in increased expression of IBTK mRNA CTD PMID:20977926 NCBI chr 8:86,625,591...86,698,661
Ensembl chr 8:86,625,597...86,698,260 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein
Bortezomib results in decreased expression of ICAM1 mRNA		 CTD PMID:18223231 PMID:20471514 PMID:25913414 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Ide insulin degrading enzyme increases expression ISO Bortezomib results in increased expression of IDE mRNA CTD PMID:20977926 NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha decreases expression ISO Bortezomib results in decreased expression of IDH3A mRNA CTD PMID:30818834 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084 		JBrowse link
G Ifi44 interferon-induced protein 44 increases expression ISO Bortezomib results in increased expression of IFI44 mRNA CTD PMID:20977926 NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844 		JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 decreases expression ISO Bortezomib results in decreased expression of IFITM1 mRNA CTD PMID:17659339 NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169 		JBrowse link
G Ifng interferon gamma multiple interactions ISO [Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] CTD PMID:30482226 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Ifrd2 interferon-related developmental regulator 2 decreases expression ISO Bortezomib results in decreased expression of IFRD2 mRNA CTD PMID:20977926 NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194 		JBrowse link
G Igf1r insulin-like growth factor 1 receptor increases response to substance ISO IGF1R gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777 		JBrowse link
G Igf2 insulin-like growth factor 2 multiple interactions
decreases response to substance		 ISO Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein]
Bortezomib results in decreased susceptibility to IGF2 protein		 CTD PMID:24055520 NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018 		JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
decreases expression		 ISO Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Bortezomib results in decreased expression of IKBKB mRNA		 CTD PMID:19417023 PMID:20471514 PMID:24085292 NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250 		JBrowse link
G Ikzf1 IKAROS family zinc finger 1 decreases expression ISO Bortezomib results in decreased expression of IKZF1 mRNA CTD PMID:20977926 NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416 		JBrowse link
G Il10 interleukin 10 affects expression ISO Bortezomib affects the expression of IL10 protein CTD PMID:19922463 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il15 interleukin 15 increases expression ISO Bortezomib results in increased expression of IL15 mRNA CTD PMID:20977926 NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820 		JBrowse link
G Il18r1 interleukin 18 receptor 1 increases expression ISO Bortezomib results in increased expression of IL18R1 mRNA CTD PMID:17895889 NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715 		JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions		 EXP Bortezomib results in increased expression of IL1B mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]		 CTD PMID:35121005 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 increases expression ISO Bortezomib results in increased expression of IL1R1 mRNA CTD PMID:17895889 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il23a interleukin 23 subunit alpha increases expression ISO Bortezomib results in increased expression of IL23A mRNA CTD PMID:17895889 NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
decreases expression
decreases secretion		 ISO
EXP		 [Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone]
Bortezomib results in increased expression of IL6 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]
Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]
Bortezomib results in decreased expression of IL6 mRNA
Bortezomib results in decreased secretion of IL6 protein		 CTD PMID:17895889 PMID:23063726 PMID:28134560 PMID:35121005 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Il7r interleukin 7 receptor increases expression
multiple interactions		 ISO Bortezomib results in increased expression of IL7R mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA		 CTD PMID:20471514 PMID:25522274 NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757 		JBrowse link
G Ino80b INO80 complex subunit B decreases expression ISO Bortezomib results in decreased expression of INO80B mRNA CTD PMID:20977926 NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456 		JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 decreases expression ISO Bortezomib results in decreased expression of IRAK1 mRNA CTD PMID:20471514 NCBI chr  X:151,768,621...151,778,521
Ensembl chr  X:151,768,777...151,778,521 		JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 increases expression ISO Bortezomib results in increased expression of IRAK2 mRNA CTD PMID:20977926 NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602 		JBrowse link
G Irf4 interferon regulatory factor 4 multiple interactions
decreases expression		 ISO 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of IRF4 protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of IRF4 protein] CTD PMID:37657595 NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070 		JBrowse link
G Irs1 insulin receptor substrate 1 decreases degradation ISO Bortezomib results in decreased degradation of IRS1 protein CTD PMID:16227402 NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122 		JBrowse link
G Isca1 iron-sulfur cluster assembly 1 increases expression ISO Bortezomib results in increased expression of ISCA1 mRNA CTD PMID:20977926 NCBI chr17:4,905,291...4,917,955
Ensembl chr17:4,905,287...4,917,955 		JBrowse link
G Itga6 integrin subunit alpha 6 decreases expression ISO Bortezomib results in decreased expression of ITGA6 mRNA CTD PMID:20977926 NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428 		JBrowse link
G Itgal integrin subunit alpha L decreases expression ISO Bortezomib results in decreased expression of ITGAL mRNA CTD PMID:20977926 NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732 		JBrowse link
G Itgav integrin subunit alpha V multiple interactions
increases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA
Bortezomib results in increased expression of ITGAV mRNA		 CTD PMID:20471514 PMID:25913414 NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639 		JBrowse link
G Itgb6 integrin subunit beta 6 increases expression ISO Bortezomib results in increased expression of ITGB6 mRNA CTD PMID:20977926 NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671 		JBrowse link
G Jak1 Janus kinase 1 decreases expression ISO Bortezomib results in decreased expression of JAK1 mRNA CTD PMID:20977926 NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression
increases expression
increases phosphorylation
multiple interactions		 ISO
EXP		 Bortezomib results in decreased expression of JUN mRNA
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form
Bortezomib results in increased phosphorylation of JUN protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]		 CTD PMID:12393500 PMID:16357177 PMID:16985072 PMID:17351739 PMID:17495969 More... NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of JUNB protein
3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of JUNB protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of JUNB protein]		 CTD PMID:37657595 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit decreases expression ISO Bortezomib results in decreased expression of JUND mRNA CTD PMID:20977926 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Kat2b lysine acetyltransferase 2B decreases expression ISO Bortezomib results in decreased expression of KAT2B mRNA CTD PMID:20471514 NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064 		JBrowse link
G Kat6b lysine acetyltransferase 6B decreases expression ISO Bortezomib results in decreased expression of KAT6B mRNA CTD PMID:20977926 NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316 		JBrowse link
G Katnal1 katanin catalytic subunit A1 like 1 increases expression ISO Bortezomib results in increased expression of KATNAL1 mRNA CTD PMID:20977926 NCBI chr12:6,094,663...6,156,114
Ensembl chr12:6,102,836...6,157,553 		JBrowse link
G Kcmf1 potassium channel modulatory factor 1 increases expression ISO Bortezomib results in increased expression of KCMF1 mRNA CTD PMID:20977926 NCBI chr 4:104,888,452...104,950,234
Ensembl chr 4:104,889,847...104,950,234 		JBrowse link
G Kctd10 potassium channel tetramerization domain containing 10 increases expression ISO Bortezomib results in increased expression of KCTD10 mRNA CTD PMID:20977926 NCBI chr12:42,230,159...42,248,792
Ensembl chr12:42,230,269...42,248,783 		JBrowse link
G Kdelr1 KDEL endoplasmic reticulum protein retention receptor 1 decreases expression ISO Bortezomib results in decreased expression of KDELR1 mRNA CTD PMID:20977926 NCBI chr 1:96,347,258...96,358,145
Ensembl chr 1:96,347,150...96,358,157 		JBrowse link
G Kdm4b lysine demethylase 4B decreases expression ISO Bortezomib results in decreased expression of KDM4B mRNA CTD PMID:20977926 NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543 		JBrowse link
G Kdm5c lysine demethylase 5C decreases expression ISO Bortezomib results in decreased expression of KDM5C mRNA CTD PMID:20977926 NCBI chr  X:21,345,459...21,387,045
Ensembl chr  X:21,345,481...21,381,870 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein CTD PMID:16985072 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Kif22 kinesin family member 22 decreases expression ISO Bortezomib results in decreased expression of KIF22 mRNA CTD PMID:20977926 NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401 		JBrowse link
G Kif9 kinesin family member 9 decreases expression ISO Bortezomib results in decreased expression of KIF9 mRNA CTD PMID:20977926 NCBI chr 8:110,459,467...110,504,492
Ensembl chr 8:110,459,383...110,505,252 		JBrowse link
G Kifc1 kinesin family member C1 decreases expression ISO Bortezomib results in decreased expression of KIFC1 mRNA CTD PMID:20977926 NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105 		JBrowse link
G Klf6 KLF transcription factor 6 increases expression ISO Bortezomib results in increased expression of KLF6 mRNA CTD PMID:20977926 NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570 		JBrowse link
G Klhdc7b kelch domain containing 7B increases expression ISO Bortezomib results in increased expression of KLHDC7B mRNA CTD PMID:20977926 NCBI chr 7:120,452,081...120,455,737
Ensembl chr 7:120,453,932...120,455,737 		JBrowse link
G Klhl20 kelch-like family member 20 increases expression ISO Bortezomib results in increased expression of KLHL20 mRNA CTD PMID:20977926 NCBI chr13:73,363,451...73,408,293
Ensembl chr13:73,363,455...73,408,337 		JBrowse link
G Klrk1 killer cell lectin like receptor K1 decreases expression ISO Bortezomib results in decreased expression of KLRK1 mRNA CTD PMID:20977926 NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459 		JBrowse link
G Kmt2a lysine methyltransferase 2A multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA CTD PMID:25913414 NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181 		JBrowse link
G Kpna2 karyopherin subunit alpha 2 increases expression ISO Bortezomib results in increased expression of KPNA2 mRNA CTD PMID:20977926 NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150 		JBrowse link
G Kri1 KRI1 homolog increases expression ISO Bortezomib results in increased expression of KRI1 mRNA CTD PMID:20977926 NCBI chr 8:19,817,005...19,831,516
Ensembl chr 8:19,817,017...19,831,392 		JBrowse link
G Krit1 KRIT1, ankyrin repeat containing increases expression ISO Bortezomib results in increased expression of KRIT1 mRNA CTD PMID:20977926 NCBI chr 4:30,299,203...30,333,366
Ensembl chr 4:30,299,203...30,333,359 		JBrowse link
G Ktn1 kinectin 1 increases expression ISO Bortezomib results in increased expression of KTN1 mRNA CTD PMID:20977926 NCBI chr15:20,913,665...21,002,588
Ensembl chr15:20,914,642...21,002,578 		JBrowse link
G Lgals2 galectin 2 decreases expression ISO Bortezomib results in decreased expression of LGALS2 mRNA CTD PMID:17659339 NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802 		JBrowse link
G Lgals8 galectin 8 increases expression ISO Bortezomib results in increased expression of LGALS8 mRNA CTD PMID:20977926 NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764 		JBrowse link
G Lgr4 leucine-rich repeat-containing G protein-coupled receptor 4 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA CTD PMID:25522274 NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899 		JBrowse link
G Lig4 DNA ligase 4 increases expression ISO Bortezomib results in increased expression of LIG4 mRNA CTD PMID:20977926 NCBI chr16:79,518,393...79,526,956
Ensembl chr16:79,518,312...79,527,040 		JBrowse link
G Lima1 LIM domain and actin binding 1 increases expression ISO Bortezomib results in increased expression of LIMA1 mRNA CTD PMID:20977926 NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473 		JBrowse link
G Limd1 LIM domain containing 1 increases expression ISO Bortezomib results in increased expression of LIMD1 mRNA CTD PMID:20977926 NCBI chr 8:123,121,363...123,168,476
Ensembl chr 8:123,122,460...123,167,714 		JBrowse link
G Lims1 LIM zinc finger domain containing 1 increases expression ISO Bortezomib results in increased expression of LIMS1 mRNA CTD PMID:20977926 NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500 		JBrowse link
G Lmna lamin A/C increases cleavage ISO Bortezomib results in increased cleavage of LMNA protein CTD PMID:20110775 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423 		JBrowse link
G Lrfn4 leucine rich repeat and fibronectin type III domain containing 4 decreases expression ISO Bortezomib results in decreased expression of LRFN4 mRNA CTD PMID:20977926 NCBI chr 1:201,888,569...201,891,861
Ensembl chr 1:201,888,569...201,891,861 		JBrowse link
G Lrrc41 leucine rich repeat containing 41 decreases expression ISO Bortezomib results in decreased expression of LRRC41 mRNA CTD PMID:20977926 NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449 		JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 increases expression ISO Bortezomib results in increased expression of LRRFIP1 mRNA CTD PMID:20977926 NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250 		JBrowse link
G Lsm4 LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated decreases expression ISO Bortezomib results in decreased expression of LSM4 mRNA CTD PMID:20977926 NCBI chr16:18,755,481...18,761,106
Ensembl chr16:18,755,484...18,760,926 		JBrowse link
G Lst1 leukocyte specific transcript 1 decreases expression ISO Bortezomib results in decreased expression of LST1 mRNA CTD PMID:20977926 NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997 		JBrowse link
G Luc7l LUC7-like increases expression ISO Bortezomib results in increased expression of LUC7L mRNA CTD PMID:20977926 NCBI chr10:15,273,340...15,307,131
Ensembl chr10:15,273,348...15,303,112 		JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA CTD PMID:25913414 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386 		JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein CTD PMID:15039284 NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868 		JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III multiple interactions ISO Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein] CTD PMID:31645432 NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249 		JBrowse link
G Mafg MAF bZIP transcription factor G increases expression ISO Bortezomib results in increased expression of MAFG mRNA CTD PMID:20977926 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] CTD PMID:24085292 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein CTD PMID:12893773 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAP2K2 mRNA CTD PMID:20977926 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions ISO alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein CTD PMID:15039284 NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression ISO Bortezomib results in decreased expression of MAP2K6 mRNA CTD PMID:20977926 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map4k3 mitogen-activated protein kinase kinase kinase kinase 3 increases expression ISO Bortezomib results in increased expression of MAP4K3 mRNA CTD PMID:20977926 NCBI chr 6:14,276,623...14,446,321
Ensembl chr 6:14,277,121...14,446,334 		JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression ISO Bortezomib results in increased expression of MAP4K4 mRNA CTD PMID:20977926 NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases expression
increases phosphorylation
decreases activity		 ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]
Bortezomib results in decreased activity of MAPK1 protein		 CTD PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk10 mitogen activated protein kinase 10 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein] CTD PMID:15173093 NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] CTD PMID:12893773 PMID:18790767 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases expression
increases phosphorylation
decreases activity		 ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]
Bortezomib results in decreased activity of MAPK3 protein		 CTD PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation		 ISO
EXP		 [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
evodiamine inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]		 CTD PMID:12893773 PMID:15039284 PMID:15173093 PMID:16985072 PMID:18559525 More... NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions		 ISO Bortezomib results in increased phosphorylation of MAPK9 protein
[Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]		 CTD PMID:16985072 PMID:18559525 PMID:18718063 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapkap1 MAPK associated protein 1 decreases expression ISO Bortezomib results in decreased expression of MAPKAP1 mRNA CTD PMID:20977926 NCBI chr 3:17,715,813...17,918,387
Ensembl chr 3:17,715,834...17,918,384 		JBrowse link
G Mapkapk2 MAPK activated protein kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAPKAPK2 mRNA CTD PMID:20977926 NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457 		JBrowse link
G Mark2 microtubule affinity regulating kinase 2 decreases expression ISO Bortezomib results in decreased expression of MARK2 mRNA CTD PMID:20977926 NCBI chr 1:204,461,029...204,526,247
Ensembl chr 1:204,461,030...204,525,652 		JBrowse link
G Maz MYC associated zinc finger protein decreases expression ISO Bortezomib results in decreased expression of MAZ mRNA CTD PMID:20977926 NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408 		JBrowse link
G Mbd1 methyl-CpG binding domain protein 1 decreases expression ISO Bortezomib results in decreased expression of MBD1 mRNA CTD PMID:20977926 NCBI chr18:67,869,870...67,884,501
Ensembl chr18:67,869,992...67,886,554 		JBrowse link
G Mbd4 methyl-CpG binding domain 4 DNA glycosylase increases expression ISO Bortezomib results in increased expression of MBD4 mRNA CTD PMID:20977926 NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982 		JBrowse link
G Mbl2 mannose binding lectin 2 increases response to substance ISO MBL2 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:228,016,439...228,024,736 JBrowse link
G Mbnl1 muscleblind-like splicing regulator 1 decreases expression ISO Bortezomib results in decreased expression of MBNL1 mRNA CTD PMID:20977926 NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368 		JBrowse link
G Mbp myelin basic protein decreases expression ISO Bortezomib results in decreased expression of MBP mRNA CTD PMID:20977926 NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases expression
decreases response to substance
increases cleavage		 ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]
Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein]
MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein		 CTD PMID:12893773 PMID:15173093 PMID:16617327 PMID:18223231 PMID:18534018 More... NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression ISO Bortezomib results in decreased expression of MCM7 mRNA CTD PMID:17659339 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063 		JBrowse link
G Mdc1 mediator of DNA damage checkpoint 1 decreases expression ISO Bortezomib results in decreased expression of MDC1 mRNA CTD PMID:20977926 NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240 		JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions
increases cleavage
affects expression		 ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]
Bortezomib affects the expression of MDM2 protein		 CTD PMID:12393500 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915 		JBrowse link
G Me1 malic enzyme 1 increases expression ISO Bortezomib results in increased expression of ME1 mRNA CTD PMID:20977926 NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304 		JBrowse link
G Mettl21a methyltransferase 21A, HSPA lysine increases expression ISO Bortezomib results in increased expression of METTL21A mRNA CTD PMID:20977926 NCBI chr 9:65,934,253...65,999,964
Ensembl chr 9:65,978,051...65,987,550 		JBrowse link
G Mettl27 methyltransferase like 27 decreases expression ISO Bortezomib results in decreased expression of METTL27 mRNA CTD PMID:20977926 NCBI chr12:21,757,545...21,766,698
Ensembl chr12:21,757,329...21,766,685 		JBrowse link
G Mex3d mex-3 RNA binding family member D decreases expression ISO Bortezomib results in decreased expression of MEX3D mRNA CTD PMID:20977926 NCBI chr 7:9,325,575...9,332,705
Ensembl chr 7:9,325,488...9,332,096 		JBrowse link
G Mfn1 mitofusin 1 decreases expression ISO Bortezomib results in decreased expression of MFN1 mRNA CTD PMID:20977926 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640 		JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression ISO Bortezomib results in decreased expression of MFNG mRNA CTD PMID:20977926 NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653 		JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions ISO Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein] CTD PMID:24193513 NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756 		JBrowse link
G Mir21 microRNA 21 increases expression ISO Bortezomib results in increased expression of MIR21 mRNA CTD PMID:20977926 NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of MKI67 protein
[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]		 CTD PMID:19372569 PMID:30482226 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Mllt11 MLLT11, transcription factor 7 cofactor increases expression ISO Bortezomib results in increased expression of MLLT11 mRNA CTD PMID:20977926 NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of MMP9 protein] CTD PMID:20696233 PMID:24333736 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mob3a MOB kinase activator 3A decreases expression ISO Bortezomib results in decreased expression of MOB3A mRNA CTD PMID:17659339 NCBI chr 7:9,010,490...9,027,888
Ensembl chr 7:9,010,587...9,027,879 		JBrowse link
G Morc2 MORC family CW-type zinc finger 2 increases expression ISO Bortezomib results in increased expression of MORC2 mRNA CTD PMID:20977926 NCBI chr14:78,529,603...78,571,375
Ensembl chr14:78,527,009...78,571,343 		JBrowse link
G Mpz myelin protein zero decreases expression EXP
ISO		 Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein CTD PMID:20830808 NCBI chr13:83,570,811...83,576,680
Ensembl chr13:83,570,811...83,576,679 		JBrowse link
G Mrpl19 mitochondrial ribosomal protein L19 increases expression ISO Bortezomib results in increased expression of MRPL19 mRNA CTD PMID:20977926 NCBI chr 4:114,521,824...114,526,053
Ensembl chr 4:114,521,824...114,526,053 		JBrowse link
G Mrpl30 mitochondrial ribosomal protein L30 decreases expression ISO Bortezomib results in decreased expression of MRPL30 mRNA CTD PMID:20977926 NCBI chr 9:40,125,352...40,136,189
Ensembl chr 9:40,125,430...40,137,257 		JBrowse link
G Mrps12 mitochondrial ribosomal protein S12 decreases expression ISO Bortezomib results in decreased expression of MRPS12 mRNA CTD PMID:20977926 NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780 		JBrowse link
G Mrps5 mitochondrial ribosomal protein S5 decreases expression ISO Bortezomib results in decreased expression of MRPS5 mRNA CTD PMID:20977926 NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291 		JBrowse link
G Msh6 mutS homolog 6 decreases expression ISO Bortezomib results in decreased expression of MSH6 mRNA CTD PMID:17659339 NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956 		JBrowse link
G Mtmr6 myotubularin related protein 6 increases expression ISO Bortezomib results in increased expression of MTMR6 mRNA CTD PMID:20977926 NCBI chr15:34,419,931...34,457,863
Ensembl chr15:34,419,903...34,457,861 		JBrowse link
G Muc1 mucin 1, cell surface associated decreases expression ISO Bortezomib results in decreased expression of MUC1 mRNA CTD PMID:20977926 NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733 		JBrowse link
G Mutyh mutY DNA glycosylase decreases expression ISO Bortezomib results in decreased expression of MUTYH mRNA CTD PMID:17659339 NCBI chr 5:130,274,034...130,286,149
Ensembl chr 5:130,274,122...130,286,146 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
increases expression
decreases expression		 ISO [Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]
Bortezomib results in increased expression of MYC protein
Bortezomib results in decreased expression of MYC protein		 CTD PMID:12902978 PMID:18641367 PMID:19417023 PMID:20022965 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor decreases expression ISO Bortezomib results in decreased expression of MYD88 mRNA CTD PMID:20471514 NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415 		JBrowse link
G Myl12a myosin light chain 12A increases expression ISO Bortezomib results in increased expression of MYL12A mRNA CTD PMID:20977926 NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580 		JBrowse link
G Myo5a myosin VA increases response to substance ISO MYO5A gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918 		JBrowse link
G Naa80 N(alpha)-acetyltransferase 80, NatH catalytic subunit decreases expression ISO Bortezomib results in decreased expression of NAA80 mRNA CTD PMID:17659339 NCBI chr 8:108,254,314...108,257,564
Ensembl chr 8:108,253,302...108,257,563 		JBrowse link
G Nab2 Ngfi-A binding protein 2 decreases expression ISO Bortezomib results in decreased expression of NAB2 mRNA CTD PMID:20977926 NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989 		JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression ISO Bortezomib results in increased expression of NABP1 mRNA CTD PMID:20977926 NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107 		JBrowse link
G Nadk NAD kinase decreases expression ISO Bortezomib results in decreased expression of NADK mRNA CTD PMID:20977926 NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322 		JBrowse link
G Nadk2 NAD kinase 2, mitochondrial increases expression ISO Bortezomib results in increased expression of NADK2 mRNA CTD PMID:20977926 NCBI chr 2:58,117,674...58,159,815
Ensembl chr 2:58,117,674...58,159,808 		JBrowse link
G Naf1 nuclear assembly factor 1 ribonucleoprotein increases expression ISO Bortezomib results in increased expression of NAF1 mRNA CTD PMID:20977926 NCBI chr16:22,837,583...22,868,320
Ensembl chr16:22,837,588...22,868,293 		JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 affects expression ISO Bortezomib affects the expression of NAIP mRNA CTD PMID:25913414 NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542 		JBrowse link
G Nap1l2 nucleosome assembly protein 1-like 2 increases expression ISO Bortezomib results in increased expression of NAP1L2 mRNA CTD PMID:20977926 NCBI chr  X:68,174,051...68,176,449
Ensembl chr  X:68,173,987...68,176,666 		JBrowse link
G Ncf4 neutrophil cytosolic factor 4 decreases expression ISO Bortezomib results in decreased expression of NCF4 mRNA CTD PMID:20977926 NCBI chr 7:109,825,420...109,843,389
Ensembl chr 7:109,826,020...109,843,389 		JBrowse link
G Nckap1 NCK-associated protein 1 increases expression ISO Bortezomib results in increased expression of NCKAP1 mRNA CTD PMID:20977926 NCBI chr 3:65,417,450...65,491,769
Ensembl chr